Introduction {#s1}
============

The ability of cortical networks to process information requires a fine spatiotemporal balance of glutamatergic excitation and GABAergic inhibition. Inhibition in these circuits arises from GABAergic interneurons (INs), which target either the perisomatic or dendritic regions of principal cells (PCs) and are embedded in the local network in feedback or feedforward ([@bib15]; [@bib37]). A subpopulation of IN expresses the neuropeptide somatostatin (SOM) and innervates the distal apical dendritic tufts of PCs and INs ([@bib35]; [@bib54]). SOM-INs act as a ubiquitous inhibitory feedback element in hippocampal and neocortical circuits, due to their preferential excitatory input from local PCs ([@bib4]; [@bib9]; [@bib45]; [@bib55]; [@bib66]; [@bib77]; [@bib82]). Besides controlling dendritic excitability and synaptic plasticity at the single-cell level, hippocampal SOM-INs contribute to the co-ordination of population activity, particularly in the theta frequency range (4--12 Hz) ([@bib26]; [@bib36]; [@bib53]), but also at higher frequencies in the beta and lower gamma band ([@bib19]; [@bib32]). They gate information flow between and within cortical areas ([@bib46]; [@bib56]) and support learning and memory processes ([@bib51]; [@bib1]; [@bib3]).

Cortical INs are themselves strongly controlled by inhibitory mechanisms produced through both ionotropic GABA~A~ receptors (GABA~A~R) and metabotropic GABA~B~Rs ([@bib42]). Indeed, SOM-INs in CA1 of the hippocampus have been shown to receive a strong GABA~A~R-mediated synaptic input from local INs, dominantly those expressing calretinin (CR) and vasoactive intestinal peptide (VIP) ([@bib74]). GABA~A~R-mediated inhibition onto INs more generally has been linked to disinhibitory network mechanisms ([@bib2]) and the emergence of coherent oscillatory network activity ([@bib6]; [@bib7]; [@bib72]; [@bib81]). In contrast, the contribution of GABA~B~Rs to network functions is less well understood ([@bib11]; [@bib17]; [@bib38]), despite the ubiquitous expression and abundant distribution of GABA~B~Rs at both pre- and postsynaptic locations on PCs and INs alike ([@bib41]; [@bib40]). We have recently shown that SOM-INs in CA1 express high levels of postsynaptic GABA~B~Rs and their activation does not activate Kir3 channels, but inhibit dendritic L-type (Ca~v~1.2) calcium channels to suppress synaptic plasticity ([@bib14]). This result raises the question: do presynaptic GABA~B~Rs contribute to short-term, direct inhibition of synaptic transmission at the input and output synapses of SOM-INs, leading to circuit level disinhibition? In fact, presynaptic GABA~B~R-mediated inhibition would be able to efficiently control IN recruitment and to functionally uncouple them from the local network ([@bib33]; [@bib76]).

In this study, we first characterized the surface expression, localization and function of presynaptic GABA~B~Rs at input and output synapses of SOM-INs in CA1 of the rodent hippocampus by combining in vitro electrophysiology with optogenetics and quantitative immunoelectron microscopy. We then assessed the impact of GABA~B~R activation on network recruitment of SOM-INs during pharmacologically induced network oscillations in vitro.

Results {#s2}
=======

Presynaptic GABA~B~Rs Strongly Inhibit Glutamatergic and GABAergic Synaptic Inputs onto SOM-INs {#s2-1}
-----------------------------------------------------------------------------------------------

As SOM-INs largely lack postsynaptic GABA~B~R mediated K^+^-currents ([@bib14]), we hypothesized that this receptor may confer presynaptic inhibition at synaptic inputs onto SOM-INs from CA1 PCs. Therefore, we performed whole-cell recordings from the INs combined with extracellular stimulation of their inputs in the *alveus* in rat acute hippocampal slices ([Figure 1](#fig1){ref-type="fig"}). We identified SOM-INs during the recordings as neurons having (1) their soma located at the *str. oriens/alveus* border, (2) high-frequency, but accommodating discharge pattern and (3) a large 'sag' in response to hyperpolarizing current steps during the recordings ([Figure 1A](#fig1){ref-type="fig"}). After the recordings, immunoreactivity for SOM was confirmed in 63 visualized INs ([Figure 1A](#fig1){ref-type="fig"}; [@bib14]); cells that were negative for SOM were excluded. Most visualized SOM-INs in rat slices showed characteristic horizontally-oriented dendrites restricted to the *str. oriens/alveus* and 25 cells (39.7%) possessed an axon projecting to the *str. lacunosum-moleculare* ([Figure 1A](#fig1){ref-type="fig"}), consistent with the morphological features of oriens*/alveus*-*lacunosum-moleculare* (OLM) INs as described previously ([@bib54]; [@bib35]). Further 2 INs (3.2%) had bistratified axons in *str. radiatum* and *oriens*, 4 (6.4%) had axons confined to *str. oriens* only. The remaining INs either had axons cut close to the soma (8 cells, 12.7%) or were not sufficiently filled to allow morphological identification (24 cells, 38.1%). This division of cell identity is comparable to that we have observed previously ([@bib15]). In an additional set of recordings from mouse slices (see below), we identified 15 SOM-INs, of which 7 were OLM cell (46.7%), 2 were bistratified cell (13.3%), the remainder had a cut axon (1 cell) or not filled sufficiently (5 cells) to be identifed morphologically.

![Synaptic inputs onto SOM-INs are strongly inhibited by presynaptic GABA~B~R activation.\
(**A**) A reconstruction of a SOM-IN showing soma and dendrites (black) and axon (red) with respect to the layers of the CA1 area. **I**nset (top left), intrinsic physiological response to current injections (500 ms duration; −250 pA to 250 pA). Inset (right), immunoreactivity for SOM (green) in the same biocytin-filled cell (bioc, blue). The arrows indicate SOM immunoreactivity in somata of the biocytin-filled (upper) and non-filled (lower) INs. Scale bar: 20 µm. (**B**, upper) EPSCs elicited in a SOM-IN by *alveus* stimulation in the presence of 10 µM bicuculline, during control (left), baclofen (10 µM, middle, control traces are overlain in red) and CGP-55,845 (CGP, 5 µM, right) bath application. (B, lower) Time-course plot of the mean EPSC amplitude in 10 SOM-INs during control, and sequential bath application of baclofen, CGP and NBQX (10 µM). (**C,D**) Summary bar graphs of EPSC amplitudes and PPRs under control conditions (Ctrl) and during baclofen and subsequent CGP application from 9 SOM-INs. (**E**) Monosynaptic IPSCs evoked by stimulation of *str. oriens* in the presence of NBQX and APV (50 µM, top) and time-course plot of the mean IPSC amplitude from 9 SOM-INs (bottom) during control, and sequential bath application of baclofen, CGP and bicuculline (Bic, 10 µM). (**F,G**) Summary bar graphs of IPSC amplitudes and PPR from 9 SOM-INs. Connected circles correspond to data obtained from a single SOM-IN in the different conditions. Statistics shown: ns -- p\>0.05, \* -- p\<0.05, \*\* -- p\<0.01, \*\*\* - p\<0.001; all from repeated measures ANOVA with Holm-Sidak post-tests. Abbreviations: Ori - *str. oriens*, Pyr - *str. pyramidale*, Rad - *str. radiatum*, L-M - *str. lacunosum-moleculare*, DG -- dentate gyrus.](elife-51156-fig1){#fig1}

In the presence of GABA~A~R antagonists (gabazine or bicuculline, both 10 µM), *alveus* stimulation produced short-latency EPSCs with an average amplitude of 77.7 ± 16.1 pA (10 cells) and a strong facilitation with a paired-pulse ratio (PPR) of 1.8 ± 0.2 in response to paired-pulses (100 µs, 50 ms interval, [Figure 1B](#fig1){ref-type="fig"}), typical of CA1 PC synapses ([@bib45]). Application of baclofen (10 μM) decreased the mean EPSC amplitude by 84% to 12.2 ± 2.2 pA (t~(d.f.19)~=3.96, p=0.001, Holm-Sidak test), but increased the PPR to 2.8 ± 0.5 (t~(d.f.25)~=2.94, p=0.025, Holm-Sidak test, [Figure 1C,D](#fig1){ref-type="fig"}) indicating a reduction in the glutamate release probability at presynaptic terminals by GABA~B~R activation. Subsequent CGP (5 μM) application to the bath in a subset of experiments (8 cells) recovered the EPSCs to baseline levels with a mean amplitude of 89.7 ± 13.7 pA (t~(d.f.25)~=0.68, p=0.502, Holm-Sidak test) and PPR of 1.8 ± 0.2 (t~(d.f.19)~=2.8, p=0.025, Holm-Sidak test, [Figure 1C,D](#fig1){ref-type="fig"}). The AMPA receptor (AMPAR) antagonist NBQX (10 μM), applied at the end of a subset of these experiments (5 cells) reduced the average EPSC amplitude by 97% to 3.5 ± 1.5 pA (U~(d.f.\ 4)~=0.0, p=0.0006, Mann-Whitney test), confirming that responses were mediated by glutamatergic synapses.

To explore whether the GABA~B~R-mediated suppression of feedback CA1 input to SOM-INs was species specific, we performed similar recordings in wild-type mice (5 cells; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Under control conditions, stimulation of the *alveus* resulted in an average EPSC amplitude of 62.1 ± 8.5 pA ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}) which following bath application of a low concentration of baclofen (2 µM) was reduced by 57% to 26.7 ± 4.9 pA (F~(d.f.2,4)~=15.9, p=0.0016, 1-way ANOVA; t = 4.9, p=0.002, Holm-Sidak test; [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). Subsequent bath application of 5 µM CGP fully reversed the observed inhibition to 101.1% of control (t = 0.01, p=0.99, Holm-Sidak test). These data confirm that strong presynaptic inhibition is present at inputs onto SOM-INs, irrespective of the species tested.

SOM-INs receive a strong GABAergic input from a subset of local CR- and VIP-expressing INs ([@bib2]; [@bib74]). We therefore asked whether GABA~A~R-mediated IPSCs in SOM-INs show a similar sensitivity to GABA~B~R activation. Paired-pulse extracellular stimulation to the *str. oriens* proximal to these recorded SOM-INs (9 cells) in the presence of AMPAR and NMDAR antagonists (10 µM NBQX and 50 µM APV) gave rise to large monosynaptic IPSCs with an average amplitude of 158.9 ± 34.4 pA and a depressing PPR of 0.82 ± 0.05 ([Figure 1D](#fig1){ref-type="fig"}). Activation of GABA~B~Rs by bath application of baclofen (10 μM) reduced the IPSC amplitude by 69% to 49.5 ± 13.2 pA (t~(d.f.16)~=5.07, p=0.0003, Holm-Sidak test), but had minimal and non-significant effect on the PPR (0.97 ± 0.05; t~(d.f.16)~=1.58, p=0.251, Holm-Sidak test; [Figure 1F,G](#fig1){ref-type="fig"}). CGP (5 μM) application recovered the IPSC amplitude to 97% of control levels (154.5 ± 27.7 pA, t~(d.f.16)~=0.205, p=0.84, Holm-Sidak test; [Figure 1F,G](#fig1){ref-type="fig"}). Application of bicuculline (10 μM) following CGP recovery inhibited the IPSCs by 94% to 9.9 ± 2.1 pA (U~(d.f.9)~=0, p=0.0006, Mann-Whitney test; [Figure 1D](#fig1){ref-type="fig"}), confirming their GABA~A~R-mediated nature. Thus, our data show that presynaptic GABA~B~Rs strongly control the strength of both excitatory and inhibitory synaptic inputs onto CA1 SOM-INs.

To examine the strong GABA~B~R-mediated inhibition at single excitatory input synapse onto SOM-INs, we next performed paired whole-cell recordings between synaptically coupled CA1 PCs and INs ([Figure 2](#fig2){ref-type="fig"}). From a total of 42 tested CA1 PC - SOM-IN paired recordings, in 5 pairs (12%) we could observe unitary synaptic coupling in response to a train of presynaptic action potentials (APs) ([Figure 2A](#fig2){ref-type="fig"}). No IPSCs elicited by SOM-INs were detected in any of the simultaneously recorded PCs.

![Unitary EPSCs from PCs onto SOM-INs are strongly inhibited by presynaptic GABA~B~Rs.\
(**A**) Reconstruction of a synaptically coupled CA1 PC (soma/dendrites in blue, axon in green) and SOM-IN pair (soma/dendrites in black, axon in red). Inset (bottom right) shows a train of APs (upper trace) evoked by a depolarizing current applied to the CA1 PC (500 pA, 500 ms) eliciting a shower of EPSCs in the voltage-clamped SOM-IN (lower trace). (**B**) Unitary EPSCs in the SOM-IN (average trace: black line; individual traces: gray lines) produced by single APs evoked by short depolarizing current pulses (1 ms, 1--2 nA) in the CA1 PC. Time course of the unitary EPSC amplitude from the same recording under control conditions and during baclofen (2 µM) and CGP (5 µM) application. (**C**) Summary bar chart of mean EPSC amplitude in 5 CA1 PC/SOM-IN pairs during control conditions (Ctrl), baclofen (Bac) and CGP steady states. (**D**) Summary data for EPSC failure rate recorded under the same conditions. Connected circles correspond to data obtained from a single PC - SOM-IN pair in the different conditions. Statistics shown: ns -- p\>0.05, \* -- p\<0.05, \*\* -- p\<0.01, \*\*\* - p\<0.001; all from repeated measures ANOVA with Holm-Sidak post-tests.](elife-51156-fig2){#fig2}

Single APs produced in the presynaptic CA1 PC resulted in short latency unitary EPSCs with an average amplitude of 7.1 ± 1.7 pA (range: 2.5--12.0 pA; [Figure 2B,C](#fig2){ref-type="fig"}) and a failure rate of 61.5 ± 7.2% in SOM-INs ([Figure 2D](#fig2){ref-type="fig"}). Application of a lower baclofen concentration (2 μM), reduced the mean EPSC amplitude by 74% to 1.6 ± 0.9 pA (t~(d.f.\ 8)~=3.96, p=0.01, Holm-Sidak test; [Figure 2B,C](#fig2){ref-type="fig"}), consistent with the strong reduction observed with extracellular stimulation (U~(d.f.13)~=24, p=0.945, Mann-Whitney test). Under this condition, the failure rate increased to 84.8 ± 6.3% (t~(d.f.8)~=3.3, p=0.022, Holm-Sidak test; [Figure 2D](#fig2){ref-type="fig"}), indicating that the release probability was significantly reduced. Subsequent application of 5 μM CGP recovered both the EPSC amplitude (t~(d.f.\ 8)~=0.18, p=0.86, Holm-Sidak test) and the failure rate (t~(d.f.\ 8)~=1.35, p=0.21, Holm-Sidak test, [Figure 2C,D](#fig2){ref-type="fig"}) to control levels.

These data, thus, confirm that GABA~B~Rs strongly inhibit excitatory synaptic inputs from local PCs onto SOM-INs, indicating a pivotal role of this receptor in controlling SOM-IN recruitment in this feedback inhibitory microcircuit.

GABA~B~R Subunits are Expressed at Presynaptic Boutons Forming Synapses onto SOM-INs {#s2-2}
------------------------------------------------------------------------------------

To investigate the molecular basis of the strong inhibition at excitatory and inhibitory inputs to SOM-INs, we next assessed GABA~B~R expression at presynaptic boutons contacting SOM-IN dendrites in *str. oriens/alveus* of CA1. We performed high-resolution quantitative SDS-FRL analysis from perfusion-fixed rat hippocampal sections ([@bib13]; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Antibodies used here targeted intracellular epitopes of the proteins of interest - receptors, ion channels, transporters and yellow fluorescent protein (YFP), therefore, they resulted in labeling of the protoplasmic face (P-face), but not the exoplasmic face (E-face), of the replicas ([Figure 3---figure supplement 1A--C](#fig3s1){ref-type="fig"}). We first double-labelled replicas for the constitutive GABA~B1~ subunit and mGluR1α, which specifically labels CA1 SOM-INs ([@bib8]). We consistently observed a high surface expression of GABA~B1~ subunits on presynaptic terminals contacting horizontal, sparsely spiny mGluR1α-immunolabelled dendrites in *str. oriens/alveus* ([Figure 3---figure supplement 1A,C](#fig3s1){ref-type="fig"}) demonstrating the presence of the receptor at virtually all synapses. To examine the presence of GABA~B~Rs at glutamatergic and GABAergic presynaptic boutons, we performed double immunolabeling for GABA~B1~ with the vesicular glutamate transporter 1 (VGluT1), which selectively labels excitatory terminals in the hippocampus. We consistently observed GABA~B1~ labeling at both VGluT1-positive and VGluT1-negative boutons with an apparently higher density of the receptor subunit in VGluT1-negative putative inhibitory terminals ([Figure 3---figure supplement 1D,E](#fig3s1){ref-type="fig"}).

To directly assess and quantify the subcellular organization and density of GABA~B~Rs on dendritic and axonal compartments of SOM-INs, we utilized an approach combining transgenic mouse strategy with the SDS-FRL immunoelectron microscopy. The SOM-Cre mouse line was crossed with the Ai32(RCL-ChR2(H134R)/EYFP) line leading to selective expression of the Channelrhodopsin2(ChR2)-YFP fusion protein in every SOM-IN. As ChR2 renders the fusion protein membrane bound, selective labeling of SOM-IN surface membranes in SDS-FRL replicas can be performed by using an antibody against YFP, thus allowing reliable identification of the INs in SDS-FRL labeling ([@bib64]; [@bib73]). Indeed, by co-labeling for YFP and mGluR1α, we found that 96% of YFP-positive dendritic shafts in the *str. oriens* (27 out of 28 dendrites) also showed immunoreactivity for this marker glutamate receptor ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), confirming that YFP was reliably expressed and detected in SOM-INs in replicas from the transgenic mice. Furthermore, the surface density of immunogold particles for GABA~B1~ on YFP-positive dendritic membranes in double-labelled replicas from the transgenic mice was comparable to that previously found in mGluR1α-positive SOM-IN dendrites from rat hippocampal CA1 (54.61 ± 2.52 particles/µm^2^ on YFP-positive mouse dendrites, [Figure 3---figure supplements 3](#fig3s3){ref-type="fig"} and 49.1 ± 4.5 particles/µm^2^ in mGluR1α-positive rat dendrites; [@bib14]) indicating a convergence between the two rodent species.

In the replicas from transgenic mice, we next performed triple labeling for GABA~B1~, YFP and Ca~v~2.1 as a marker for presynaptic active zone ([@bib5]; [Figure 3](#fig3){ref-type="fig"}). In good agreement with the findings from rat, we observed an abundant surface expression of the receptor subunit on presynaptic terminals in contact with YFP-positive dendritic shafts of SOM-INs in the *str. oriens* in the mice ([Figure 3A](#fig3){ref-type="fig"}). Immunoparticles for GABA~B1~ were mainly confined to, and distributed non-homogeneously over, the active zones (AZs) of terminals ([Figure 3B,C](#fig3){ref-type="fig"}), which were recognized by their high density of intramembrane particles on the P-face of the invaginated plasma membrane and a strong immunolabeling for Ca~v~2.1 ([@bib5]). Furthermore, receptor subunits were occasionally seen along the extrasynaptic membrane of presynaptic boutons ([Figure 3B,C](#fig3){ref-type="fig"}).

![Localization of the GABA~B1~ subunit to axon terminals contacting SOM-IN dendrites in *str. oriens.*\
(**A**) Electron micrograph showing the localization of GABA~B1~ (6 nm particles) to synaptic membranes, identified by immunoreactivity for Ca~V~2.1 (12 nm), and extrasynaptic membrane of axon terminals of putative excitatory (b1) and inhibitory (b2, b3) neurons making synapses onto a dendrite (Den~SOM~) of a mouse ChR2-YFP-expressing (18 nm) SOM-IN. (**B,C**) High magnification views of the boxed areas of the SOM-IN dendrite in (**A**). Note that there are three other presumed excitatory boutons (b4-6) contacting dendrite of the IN. Abbreviations: P-face, protoplasmic face; E-face, exoplasmic face; cf, cross-fractured face. Scale bars: 200 nm.](elife-51156-fig3){#fig3}

We next asked to what extent GABA~B1~ surface localization is segregated between excitatory and inhibitory presynaptic terminals targeting dendritic shafts of SOM-INs. To address this question, we performed triple-immunolabeling for GABA~B1~, YFP and either VGluT1 or vesicular GABA transporter (VGAT), which selectively label boutons of glutamatergic and GABAergic neurons, respectively ([Figure 4](#fig4){ref-type="fig"}). In these replicas, we consistently observed labeling for GABA~B1~ in both populations of terminals, but immunoreactivity for the receptor subunit was significantly higher in VGAT-positive and VGluT1-negative inhibitory terminals (43.00 ± 6,61 particles/µm^2^, n = 36) compared to VGAT-negative and VGluT1-positive excitatory presumed PC axon terminals (17.36 ± 2.13 particles/µm^2^, n = 60; p\<0.0001, Mann-Whitney test; [Figure 4B--D](#fig4){ref-type="fig"}). These data demonstrate that both GABAergic and glutamatergic terminals forming synapses onto SOM-INs contain large numbers of GABA~B~Rs, consistent with electrophysiological findings demonstrating a robust presynaptic inhibition at inhibitory and excitatory inputs, however, with a substantial difference in the surface density between the two bouton populations.

![GABA~B1~ expression on inhibitory and excitatory axon terminals forming synapses onto SOM-IN dendrites.\
(**A**) Electron micrographs showing immunogold labeling for GABA~B1~ (6 nm, arrows) on VGAT-immunonegative (b~VGAT-~) and VGAT-immunopositive (b~VGAT+;~12 nm) axon terminals contacting a ChR2-YFP-immunopositive (18 nm) dendritic shaft of a SOM-IN (Den~SOM~). (**B**) Expanded view of the VGAT-immunonegative terminal identified in (**A**), with GABA~B1~ labeling highlighted (red overlay). (**C**) Expanded view of the VGAT-immunopositive terminal identified in (**A**), with GABA~B1~ highlighted. (**D**) Summary bar graph of GABA~B1~ labeling density on excitatory (VGAT- and VGluT1+) and inhibitory (VGAT+ and VGluT1-) axon terminals. Data from individual compartment are shown as open circles with numbers of analyzed terminals in parentheses. Density of GABA~B1~ is significantly higher in inhibitory boutons compared to excitatory terminals (\*\*\*\*p\<0.0001, Mann-Whitney test). Abbreviations: E-face, exoplasmic face; P-face, protoplasmic face; cf, cross-fractured face. Scale bars: 200 nm.](elife-51156-fig4){#fig4}

Activation of GABA~B~Rs Inhibits GABA Release from SOM-IN Axon Terminals {#s2-3}
------------------------------------------------------------------------

We next asked whether the output synapses of SOM-INs onto CA1-PCs are inhibited by GABA~B~ autoreceptors. Given that in acute slice preparations SOM-INs have a very low connection probability to CA1-PCs ([@bib4]), we utilized ChR2 activation of SOM-IN axons in SOM-Cre transgenic mice ([@bib62]; [@bib82]) to examine the synaptic output of SOM-INs ([Figure 5](#fig5){ref-type="fig"}). For this purpose hippocampal slices were prepared from SOM-Cre transgenic mice injected with rAAVs containing ChR2 and tdTomato between inverted incompatible tandem loxP sites. This viral strategy allowed spatially restricted expression of ChR2 in the CA1. The expression pattern which was detected by the fluorescence intensity of tdTomato reporter was highest in *str. oriens,* primarily localized to somata and dendrites, and *str. lacunosum-moleculare* showing a more diffuse axonal labeling ([Figure 5A](#fig5){ref-type="fig"}). At the cellular level this expression was restricted to SOM-INs ([Figure 5A](#fig5){ref-type="fig"}, inset, bottom).

![SOM-IN output synapses are inhibited by GABA~B~Rs.\
(**A**) Confocal image stack of a recorded and biocytin-filled CA1 PC (white pseudocolor) in a slice from SOM-Cre transgenic mouse transfected with ChR2-tdTomato (tom, red). The slice was counterstained with DAPI (blue) to reveal hippocampal layering, including the cell body layer (Pyr). Inset (right), plot of the fluorescence intensity in the red channel for the ChR2-tdTomato fusion protein across CA1 layers. Inset (bottom), co-localization of tdTomato (tom, red) with SOM immunofluorescence (green). Scale bars: 50 µm (main) and 20 µm (inset). (**B**, upper) IPSCs recorded in a CA1 PC following photo stimulation of SOM-IN axons in the CA1. Individual sweeps (gray) are overlaid with the averaged traces (in black) for control, baclofen (10 µM) and CGP (5 µM) conditions. (B, lower) Time-course plot of IPSC amplitudes obtained from the CA1 PC during control and sequential bath application of baclofen and CGP. (**C**) Summary bar chart of mean IPSC amplitudes from 6 CA1 PCs in control, baclofen and CGP conditions. (**D**) Summary bar chart of IPSC amplitudes from 7 CA1 PCs with the same pharmacological tests, but in the continuous presence of SCH-23,390 (SCH, 10 µM) to block Kir3 channels. (**E**) Mean IPSC amplitudes normalized to control in the presence of baclofen (6 cells), SCH and baclofen (7 cells), and CGP alone (4 cells). Connected circles correspond to data obtained from single PCs under the different conditions. Statistics shown: ns -- p\>0.05, \*p\<0.05, \*\*p\<0.01 from Holm-Sidak tests.](elife-51156-fig5){#fig5}

Optogenetic activation of SOM-IN axons in the *str. lacunosum-moleculare* resulted in temporally-aligned IPSCs in CA1 PCs with an average peak amplitude of 14.0 ± 3.6 pA (6 cells, [Figure 5B,C](#fig5){ref-type="fig"}). Baclofen application markedly reduced the optically-evoked IPSC amplitudes by 61% to 5.3 ± 1.3 pA (t~(d.f.\ 8)~=4.31, p=0.007, Holm-Sidak test, [Figure 5B,C](#fig5){ref-type="fig"}) indicating the presence of presynaptic GABA~B~Rs at SOM-IN output synapses. Subsequent CGP bath-application (4 cells) recovered the IPSC amplitude to 119% of control (15.2 ± 3.4 pA, t~(d.f.\ 8)~=0.12, p=0.90, Holm-Sidak test, [Figure 5B,C](#fig5){ref-type="fig"}). However, GABA~B~R activation also produced a strong I~WC~ of 49 ± 15 pA postsynaptically (6 cells, [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}), plausibly due to Kir3 channel opening in CA1 PC dendrites ([@bib20]). This postsynaptic conductance may shunt the evoked IPSCs and contribute to their reduced amplitudes during baclofen application. Therefore, we isolated the contribution of presynaptic GABA~B~Rs in a set of experiments in which we pre-applied the Kir3 channel blocker SCH-23,390 (SCH, 10 µM; [@bib44]). Pre-application of SCH reduced the baclofen-induced I~WC~ in CA1 PCs to 19 ± 3 pA (7 cells, t~(d.f.\ 11)~=1, p=0.002, Mann-Whitney test, [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). In the presence of SCH, the IPSC elicited by optogenetic activation of SOM-IN axons had an average amplitude of 7.0 ± 1.3 pA ([Figure 5D](#fig5){ref-type="fig"}) and tended to be smaller than IPSCs elicited in PCs recorded in the absence of SCH, albeit not significantly so (U~(d.f.\ 11)~=9, p=0.10, Mann-Whitney test). Baclofen application under this condition inhibited the IPSC by 70% to 2.3 ± 0.4 pA (t~(d.f.\ 7)~=4.82, p=0.002, Holm-Sidak test, [Figure 5D](#fig5){ref-type="fig"}). The effect of baclofen was reversed by consecutive CGP application ([Figure 5D](#fig5){ref-type="fig"}). The baclofen-induced presynaptic inhibition of SOM-INs IPSCs in the presence of SCH was comparable to that of baclofen applied alone (t~(d.f.\ 14)~=0.2, p=0.84, Holm-Sidak test, [Figure 5E](#fig5){ref-type="fig"}), indicating that the observed reduction in the IPSC amplitude was not contaminated by a Kir3-mediated postsynaptic shunting effect in the PCs. These data, thus, confirm that GABA~B~Rs are present in the axon terminals of SOM-INs and strongly inhibit the synaptic output of these INs. Although recent observations indicate that ChR2 expression can interfere with presynaptic GABA~B~R function ([@bib48]), the strong inhibition observed in our study argues against such a scenario under our experimental conditions.

Presynaptic GABA~B~Rs are Present at High Density on Axon Terminals of SOM-INs {#s2-4}
------------------------------------------------------------------------------

Our electrophysiological data indicate the presence of functional presynaptic GABA~B~Rs in axon terminals of SOM-INs. Therefore, we next examined the surface density and subcellular organization of GABA~B1~ in axon terminals of the INs by quantitative SDS-FRL immunoelectron microscopy in replica samples from the *str. lacunosum-moleculare* of CA1 ([Figure 6](#fig6){ref-type="fig"}) using the same ChR2-YFP-based approach as described above. Triple-immunolabeling of freeze-fracture replicas for YFP, GABA~B1~ and Ca~v~2.1 demonstrated a high number of GABA~B1~ over the plasma membrane of all analyzed YFP-immunoreactive boutons ([Figure 6A--C](#fig6){ref-type="fig"}). There was no significant difference in the density of immunoparticles for the receptor subunit on YFP-positive terminals (45.57 ± 2.31 particles/µm^2^, n = 66) of SOM-INs and YFP-negative putative PC boutons (41.56 ± 4.71/µm^2^, n = 41; p=0.099, Mann-Whitney test) ([Figure 6D](#fig6){ref-type="fig"}). Furthermore, detailed analysis revealed that 20% and 37% of the terminals possess high number of synaptic ([Figure 6A](#fig6){ref-type="fig"}) and perisynaptic ([Figure 6B](#fig6){ref-type="fig"}) receptors, respectively, whereas 43% of them contain exclusively extrasynaptic GABA~B1~ ([Figure 6C](#fig6){ref-type="fig"}). These data suggest a substantial heterogeneity among SOM-IN axon terminals in terms of ultrastructural localization of presynaptic GABA~B~Rs.

![GABA~B1~ subunit expression and localization on SOM-IN axon terminals.\
(**A--C**) Electron micrographs showing GABA~B1~ (6 nm particles, red overlay) localized to the active zone (az) (**A**), identified by immunolabeling for Ca~v~2.1 (12 nm, green overlay), to the perisynaptic membrane (**B**) and to the extrasynaptic domain (**A--C**) of YFP+ (18 nm) boutons (b) of SOM-INs. Note that extrasynaptic Ca~v~2.1 channels were not highlighted in (**A**) and (**B**). Arrowheads indicate docked and predocked vesicles on cross-fractured face (cf) of a bouton in (**A**). (**D**) Summary bar chart of the average GABA~B1~ density on YFP+ boutons, compared to nearby YFP- boutons. Data from individual compartment are shown (open circles) with number of analyzed terminals in parentheses. ns -- p\>0.05. Mann-Whitney test. Scale bars: 200 nm.](elife-51156-fig6){#fig6}

Presynaptic GABA~B~Rs Functionally Uncouple SOM-INs from the Local Microcircuit {#s2-5}
-------------------------------------------------------------------------------

SOM-INs participate in synchronized hippocampal network oscillations - in particular theta (4--12 Hz), but also gamma frequency (30--100 Hz) activity ([@bib26]; [@bib30]; [@bib33]; [@bib53]). Given the near complete inhibition of excitatory, as well as inhibitory, synaptic inputs onto SOM-INs by presynaptic GABA~B~Rs, we asked whether this inhibition was able to functionally uncouple SOM-INs from network oscillations ([Figure 7](#fig7){ref-type="fig"}).

![Presynaptic GABA~B~R-mediated inhibition functionally uncouples SOM-INs from the local network.\
(**A**) Dual extracellular field (upper) and whole-cell (lower) recordings from a CA1 SOM-IN in longitudinal acute hippocampal slice during theta frequency oscillations induced by bath application of 50 µM carbachol. Representative traces are shown in control conditions (left), and during application of baclofen (2 µM, middle), or subsequent application of CGP (5 µM, right). (**B**) Spectral analysis of the field oscillations under control conditions (grayscale), during baclofen (Bac, green) and subsequent CGP (magenta) application (7 slices). Inset, bar chart of the average peak power for the three pharmacological conditions. (**C**) Spike triggered average of the field potential (gray trace)± 75 ms from the AP in a SOM-IN (blue, superimposed; left) illustrating the firing preference at the rising phase of the oscillations. Inset (right), polar plot of the phase preference of SOM-IN discharge with respect to the oscillatory cycle. (**D**) Summary bar chart of the average discharge frequency of SOM-INs (7 cells) during theta frequency activity in control conditions and in the presence of baclofen or CGP. (**E--H**) Corresponding data for gamma activity induced by 2 mM kainate puff application to *str. radiatum* of CA1 in horizontal hippocampal slices. (**I**) Mean discharge probability of SOM-INs plotted as a function of the phase of gamma under control conditions (left), in the presence of baclofen (middle, with a bias current applied to hold the membrane potential of the SOM-IN close to firing threshold), and in the presence of CGP (right, without bias current). Statistics shown: ns -- p\>0.05, \*\* - p\<0.01, derived from repeated-measures ANOVA.](elife-51156-fig7){#fig7}

First, we induced slow, theta frequency oscillations in hippocampal slices by bath applying carbachol (50 μM; [Figure 7A](#fig7){ref-type="fig"}). We recorded extracellular theta activity in 8 slices and in 5 of these slices SOM-INs were recorded simultaneously to the local field potential. The peak power of the oscillatory activity in the field was 27.5 ± 7.0 μV^2^ at a frequency of 9.8 ± 1.5 Hz ([Figure 7B](#fig7){ref-type="fig"}). During the oscillations, SOM-INs had an average discharge frequency of 13.0 ± 3.2 Hz with the APs occurring at the rising phase of the theta cycle ([Figure 7C](#fig7){ref-type="fig"}), consistent with the discharge pattern observed in vivo ([@bib24]). Application of 2 μM baclofen resulted in a strong, 78% reduction in the theta peak power to 8.8 ± 3.3 μV^2^ (t~(d.f.8)~=3.8, p=0.015, Holm-Sidak test; [Figure 7A,B](#fig7){ref-type="fig"}). The reduction in theta power was complemented by a near-complete loss of SOM-IN discharge (mean frequency of 0.4 ± 0.2 Hz; t~(d.f.\ 8)~=3.3, p=0.03, Holm-Sidak test, [Figure 7A,D](#fig7){ref-type="fig"}). Both the theta peak power (21.5 ± 5.0 μV^2^; t~(d.f.\ 8)~=1.22, p=0.26, Holm-Sidak test; [Figure 7B](#fig7){ref-type="fig"}) and the discharge frequency (14.1 ± 4.0 Hz; t~(d.f.\ 8)~=0.12, p=0.91, Holm-Sidak test; [Figure 7D](#fig7){ref-type="fig"}) were fully reversed by subsequent bath application of 5 μM CGP, confirming that the silencing of SOM-INs was mediated by GABA~B~Rs. Recordings from CA1 PCs (4 cells) showed that their peak discharge frequency (control: 3.9 ± 1.5 Hz) was markedly reduced, but not abolished during baclofen application (1.4 ± 0.9 Hz; t~(d.f.3)~=3.7, p=0.025, Holm-Sidak test), reflecting that the effect of GABA~B~R activation had a network wide impact. The discharge of PCs, similar to that of the INs, was fully recovered by CGP application (4.1 ± 1.4 Hz; t~(d.f.3)~=1.21, p=0.258, Holm-Sidak test).

SOM-INs are also recruited to gamma oscillations ([@bib71]), therefore, we next tested the effects of presynaptic GABA~B~R activation on SOM-IN firing during this faster activity pattern. Puff application of kainate (2 mM, 100 ms) to *str. radiatum* at a distance of \~100 μm from the recorded SOM-IN, resulted in large amplitude fast gamma oscillations in the local field potential recorded from the *str. radiatum,* which lasted 5--10 s ([Figure 7E](#fig7){ref-type="fig"}). These oscillations had a peak power of 52.6 ± 14.3 μV^2^ at 61.1 ± 4.4 Hz ([Figure 7F](#fig7){ref-type="fig"}). During the kainate-induced gamma oscillations SOM-INs fired at 7.7 ± 2.0 Hz (6 cells, [Figure 7H](#fig7){ref-type="fig"}), comparable to that observed during theta oscillations (U~(d.f.\ 9)~=7, p=0.16, Mann-Whitney test). Individual APs in SOM-INs preferentially occurred at the ascending phase of gamma oscillation, on average −15 ± 10° before the peak of the oscillatory cycle ([Figure 7G,I](#fig7){ref-type="fig"}) indicating a high correlation and tight phase relationship to local network activity, despite their low discharge frequency. Bath application of 2 μM baclofen reduced the peak power of gamma oscillations by \~45% to 28.7 ± 12.0 μV^2^ (F~(d.f.\ 2,10)~=5.13, p=0.029, 1-way ANOVA; [Figure 7F](#fig7){ref-type="fig"}) with minimal effect on the frequency (65.5 ± 3.8 Hz, t~(d.f.10)~=1.1, p=0.51, Holm-Sidak test). Baclofen application also produced a near-complete loss of APs in SOM-INs (6 cells) reducing the discharge frequency to 0.7 ± 0.2 Hz (t~(d.f.5)~=3.6, p=0.04, Holm-Sidak test, [Figure 7H](#fig7){ref-type="fig"}). In contrast, baclofen application only marginally affected the discharge frequency of CA1 PCs under the same conditions (3 cells) reducing it from 9.6 ± 2.2 Hz to 7.9 ± 3.9 Hz (t~(d.f.2)~=0.7, p=0.80, Holm-Sidak test).

Given the near-complete loss of SOM-IN discharge, it was not possible to assess whether presynaptic GABA~B~R activation led to a breakdown of SOM-IN phase coupling to the oscillations. Therefore, we applied a depolarizing current to SOM-INs to promote their firing in the presence of baclofen. When SOM-INs were held near their rheobase current (106 ± 31 pA; [Figure 7I](#fig7){ref-type="fig"}, middle) in the presence of 2 µM baclofen, they fired at low frequency (2.9 ± 0.6 Hz). Under these conditions, the APs showed no preference to the phase of gamma activity (F~(d.f.\ 18,57)~=1.8, p=0.048, 2-way repeated-measures ANOVA). The discharge frequency (11.6 ± 3.2 Hz, p=0.22, Holm-Sidak test, compared to control conditions; [Figure 7H](#fig7){ref-type="fig"}) as well as the phase preference (25 ± 22°, [Figure 7I](#fig7){ref-type="fig"}, right) recovered during subsequent application of CGP (5 µM, without bias current).

To confirm that the strong inhibition of SOM-IN discharge during gamma oscillations was not species specific, we performed the same experiments in acute hippocampal slices from mice ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Puff application of kainate to *str. radiatum* produced reliable gamma oscillations with a peak power of 52.8 ± 19.2 µV^2^ at a frequency of 44.9 ± 9.4 Hz (4 slices, [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). Bath application of 2 µM baclofen reduced the peak power to 36.6 ± 13.2 µV^2^ (F~(d.f.\ 2,7)~=38.4, p=0.0002 1-way ANOVA; p=0.001, Holm-Sidak test; [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Simultaneous intracellular recording from SOM-INs during the kainate-puff-induced gamma oscillation revealed a discharge in the theta range with a mean frequency of 7.9 ± 0.9 Hz under control conditions. Similar to the observations in rat slices, application of baclofen also strongly attenuated discharge to 1.6 ± 0.7 Hz in mouse SOM-INs (t~(d.f.\ 7)~=6.0, p=0.0.001, Holm-Sidak test; [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). The oscillatory power, as well as the spike rate recovered with subsequent 5 µM CGP bath-application in 2 SOM-INs tested ([Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). These results are consistent with an uncoupling of SOM-INs from the network by presynaptic GABA~B~R activation in both rats and mice.

To demonstrate that the reduction in spiking was due to a local, not global reduction in synaptic transmission and excitability (as caused by bath application of baclofen), we performed experiments in which we focally applied baclofen (2 mM) via a second puff electrode in close proximity to the SOM-IN somata ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Under control conditions, the peak power of gamma oscillations induced by the kainate puff to the *str. radiatum* was 48.8 ± 11.2 µV^2^ at 37.0 ± 2.4 Hz in these experiments ([Figure 7---figure supplement 2A,B](#fig7s2){ref-type="fig"}). Focal puff application of baclofen to *str. oriens* had no significant effect on the peak power of gamma activity in 8 slices tested (37.6 ± 9.3 µV^2^; F~(d.f.\ 2,16)~=0.33, p=0.72; 1-way ANOVA; p=0.82, Holm-Sidak test; [Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}). Despite no change in peak gamma power, the focal baclofen application produced a near complete abolition of SOM-IN discharge from 10.2 ± 3.7 Hz under control conditions to 0.1 ± 0.1 Hz during the baclofen puff in 6 SOM-INs (F~(d.f.\ 2,13)~=4.7, p=0.028 1-way ANOVA; p=0.032, Holm-Sidak test; [Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}). The reduction in SOM-IN firing was reversed to 7.8 ± 1.7 Hz by bath application of 5 µM CGP during the baclofen puff in 4 cells (Compared to control: p=0.54, Holm-Sidak test) confirming the GABA~B~R dependence of this effect.

In summary, GABA~B~R-mediated inhibition is very strong at synaptic inputs to SOM-INs and can functionally uncouple them from the local network, silencing these INs during oscillatory activity.

Discussion {#s3}
==========

In the current study we show that excitatory and inhibitory axon terminals converging onto SOM-INs express high levels of GABA~B~Rs and activation of the receptors leads to strong inhibition of transmission at these synapses. The synaptic output of SOM-INs onto CA1 PC dendrites is similarly inhibited by GABA~B~R activation. We find that the strong presynaptic GABA~B~R inhibition observed is sufficient to silence SOM-INs during in vitro theta and gamma oscillations. Combined, these data provide strong evidence that SOM-INs can be silenced and uncoupled from hippocampal microcircuits by GABA~B~R-mediated presynaptic inhibition during co-ordinated network activity when extracellular GABA levels surge ([@bib63]).

Presynaptic GABA~B~R Activation Suppresses Synaptic Inputs onto SOM-IN {#s3-1}
----------------------------------------------------------------------

The primary excitatory synaptic input to SOM-INs is from CA1 PCs, making these INs a major feedback inhibitory element in cortical circuits ([@bib4]; [@bib45]; [@bib66]). Previous studies have demonstrated that PC synapses onto SOM-INs produce small depolarization, with high failure rates, and strong frequency dependent facilitation, indicative of a low initial release probability synapse ([@bib59]; [@bib67]; [@bib77]). This low basal synaptic transmission onto SOM-INs has been suggested to arise from multiple presynaptic modulatory pathways, including group II and III mGluRs ([@bib66]; [@bib50]) and 5-HT~1A~ receptors in the hippocampus ([@bib10]). In contrast, nicotinic acetylcholine receptors have been recently shown to boost neurotransmission at the input synapses of SOM-INs in the neocortex ([@bib77]). Our results reveal that GABA~B~Rs are also abundant at presynaptic terminals onto SOM-INs, at both synaptic and extrasynaptic membranes. While we did not observe evidence for tonic presynaptic GABA~B~R activation under our experimental conditions, agonist activation consistently produced inhibition of the glutamatergic input onto SOM-INs, sufficient to strongly inhibit monosynaptic and unitary EPSCs with concomitant changes in failure rate and PPR, indicative of a presynaptic locus of action. Plausibly, during periods of high network activity, as observed in vivo, GABA spill-over from local inhibitory synapses may readily activate GABA~B~Rs ([@bib63]; [@bib58]) in a dynamic, state-dependent manner. However, higher ambient levels of GABA could also produce a tonic level of GABA~B~R activation, contributing to the weak glutamatergic transmission from PCs to SOM-IN, through heterosynaptic receptor activation ([@bib76]).

Similar to glutamatergic synapses, we found a consistent, high level of surface expression of GABA~B~Rs and a strong presynaptic inhibition at GABAergic synapses onto SOM-INs. Previous studies indicate that VIP/CR-containing INs account for 70% of all inhibitory synapses onto SOM-INs ([@bib2]; [@bib74]). As such, we infer that the output of VIP/CR INs is strongly controlled by GABA~B~ autoreceptors. While the precise temporal pattern of this inhibitory synaptic input to SOM-INs is not known, the strong suppression of transmission during GABA~B~R activation is likely to contribute to the reduced phase relationship and uncoupling of these INs from the local network.

GABA~B~R Expression and Function at the Inhibitory Synaptic Output of SOM-IN {#s3-2}
----------------------------------------------------------------------------

The major SOM-IN output is onto the distal apical dendrites of PCs, and also other INs in hippocampal CA areas ([@bib35]). Their postsynaptic effects are primarily mediated by GABA~A~R ([@bib33]; [@bib52]), but slow GABA~B~R effects have also been observed in hippocampal and neocortical PCs ([@bib33]; [@bib52]; [@bib76]; [@bib57]), indicating that in addition to neurogliaform cells, SOM-INs may contribute to GABA volume transmission ([@bib69]; [@bib61]; [@bib58]). Indeed, SOM-INs can produce strong GABA~B~R-mediated heterosynaptic inhibition at excitatory synapses onto cortical PCs in line with a role in volume transmission ([@bib76]). The observed high density of GABA~B~Rs in SOM-IN axon terminals and the strong depression of their inhibitory output during receptor activation in our optogenetic experiments demonstrate that GABA~B~ autoreceptors dynamically regulate GABA release from these synapses. However, about half (57%) of SOM-IN boutons possessed GABA~B~Rs localized within or in direct apposition to the presynaptic active zone, whereas essentially all terminals contained extrasynaptic GABA~B~R - a subcellular distribution pattern observed at other cortical synapses ([@bib40]). This suggests that a functional dichotomy may exist where most SOM-IN synapses are regulated by ambient GABA levels, with approximately half of synapses also inhibited by GABA~B~ autoreceptors. The cellular sources of GABA involved in heterosynaptic inhibition at the output of SOM-INs is likely to be distinct from those at the input synapses, however their effects could converge to uncouple the INs from the network under specific conditions. Alternatively, this distribution pattern may demonstrate a high degree of surface dynamics of presynaptic GABA~B~Rs reflecting the activity level of the INs. This observed heterogeneity of GABA~B~R compartmentalization and its functional impact in SOM-IN outputs should be the subject of further studies.

Role of SOM-INs and GABA~B~Rs in Network Activity {#s3-3}
-------------------------------------------------

SOM-INs are well known to participate in oscillatory activity intrinsic to cortical circuits ([@bib25]; [@bib30]; [@bib36]; [@bib53]; [@bib55]; [@bib60]; [@bib71]). In good agreement with previous findings, both in vitro and in vivo ([@bib26]; [@bib33]; [@bib36]; [@bib78]), we observed that hippocampal SOM-INs discharge phase-locked to the field oscillation during both theta and gamma rhythms. These two oscillatory patterns in vitro were sensitive to low, presynaptic-selective concentrations of baclofen ([@bib21]; [@bib80]). This result is complementary to previous findings that GABA~B~R antagonists increase the oscillatory power in these two frequency bands ([@bib34]; [@bib47]) and plausibly reflects circuit-wide disinhibition of neuronal excitability and transmission, enhancing phasic modulation of the network by fast inhibition. However, the sensitivity of the two oscillatory patterns to GABA~B~R activation was differential in our experiments: while theta rhythm was almost completely abolished, gamma activity persisted albeit with a reduced power. The high sensitivity of theta activity to baclofen may reflect an inherent lability of in vitro theta oscillations. Indeed, only a few publications have reported reliable theta oscillations in ex vivo preparations ([@bib23]; [@bib25]; [@bib27]) which might be due to the strong reliance of an intact connection from the entorhinal cortex or the septum ([@bib18]). However, given the proposed central role of SOM-INs in the generation of theta activity ([@bib24]; [@bib25]; [@bib30]; [@bib36]; [@bib65]), synaptic uncoupling of the INs by presynaptic GABA~B~Rs may also be causally related to the abolished theta activity. In this context the persistence of gamma oscillations could be explained by their microcircuit mechanisms involving other IN types, in particular fast-spiking basket cells ([@bib6]; [@bib7]; [@bib28]).

Pharmacological models of gamma do not fully reflect the nuances of in vivo activity, and as such rarely does gamma exist as a prolonged 5--10 s barrage, but rather occurs co-generated with theta as nested short bursts both in the hippocampus and in the neocortex ([@bib16]; [@bib34]; [@bib68]). As SOM-INs are recruited to these oscillations they rhythmically discharge and provide inhibition to the apical dendrites of PCs. In the CA1, this inhibition gates the entorhinal inputs to PCs ([@bib46]) and has an essential role in learning and memory processes ([@bib51]). Our results show that presynaptic GABA~B~Rs are strategically positioned at both input and output synapses of SOM-INs in this generic cortical microcircuit motif, and can exert strong suppression on transmission. As SOM-IN recruitment and their precisely-timed discharge are primarily defined by their excitatory input from PCs ([@bib33]; [@bib77]) the strong suppression by GABA~B~Rs alone at this synapse, may be sufficient to uncouple and silence SOM-INs. However, the parallel suppression of GABAergic input synapses will leave the SOM-INs with minimal phasic synaptic control from the active network. Silencing of SOM-IN firing allows for a breakthrough of multi-sensory inputs from the temporoammonic pathway onto hippocampal PCs, leading to strengthened inhibition and suppressed plasticity at intrahippocampal connections ([@bib46]). The differential sensitivity of gamma and theta oscillations further suggests that the uncoupling of SOM-INs from the network by GABA~B~R activation may also modify the balance of these activity patterns. GABA~B~R-mediated suppression of SOM-IN output provides a convergent mechanism for the modulation of this feedback microcircuit. However, in view of the wide spatial separation of input and output synapses in *str. oriens* and str. *lacunosum-moleculare*, ambient GABA levels, and thus GABA~B~R activation, likely displays both temporal and pathway specific separation.

Taken together, the data we present suggest that the activity of SOM-INs, a major feedback element in cortical circuits, is strongly regulated by presynaptic GABA~B~Rs at their input and output synapses. The suppression of synaptic transmission serves to functionally silence and uncouple SOM-INs from ongoing coordinated network activity. These actions of GABA~B~Rs can fine tune inhibition/excitation balance in a compartment specific-manner and thereby tightly control the routing of information between intra- and extrahippocampal pathways.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                         Source or\                                                       Identifiers                                                                                          Additional\
  (species) or\                                                                         reference                                                                                                                                                             information
  resource                                                                                                                                                                                                                                                    
  --------------------------------- --------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Genetic reagent (R. norvegicus)   Wild-type rat                                       Charles River                                                    Crl:WI                                                                                               Rats used for immunoelectron microscopy

  Genetic reagent (R. norvegicus)   vGAT-YFP rat                                        PMID: [17517679](https://www.ncbi.nlm.nih.gov/pubmed/17517679)                                                                                                        Rats used for acute slice experiments

  Genetic reagent (*M. musculus*)   Wild-type mouse                                     Charles River                                                    C57/Bl6J CRL                                                                                         Mice used for acute slice experiments

  Genetic reagent (*M. musculus*)   Som-Cre mouse                                       Jackson Laboratory; 013044                                       Ssttm2.1(cre)Zjh/J                                                                                   

  Genetic reagent (*M. musculus*)   Ai32 mouse                                          Jackson Laboratory; 024109                                       RCL-ChR2(H134R)/EYFP                                                                                 

  Antibody                          Anti-GFP                                            Aves labs, USA                                                   Aves labs:GFP-1010                                                                                   chicken polyclonal\
                                                                                                                                                                                                                                                              (1:25000)

  Antibody                          Anti- Cav2.1                                        Frontier Institute, JAPAN                                        Frontier Institute:VDCCa1A-GP-Af810; RRID:[AB_2571851](https://scicrunch.org/resolver/AB_2571851)    guinea pig polyclonal\
                                                                                                                                                                                                                                                              (1:50)

  Antibody                          Anti- VGAT                                          Frontier Institute, JAPAN                                        Frontier Institute. VGAT-GP-Af1000; RRID:[AB_2571624](https://scicrunch.org/resolver/AB_2571624)     guinea pig polyclonal\
                                                                                                                                                                                                                                                              (1:44)

  Antibody                          Anti-VGLUT1                                         Frontier Institute, JAPAN                                        Frontier Institute: VGluT1-Go-Af310; RRID:[AB_2571617](https://scicrunch.org/resolver/AB_2571617)    goat polyclonal\
                                                                                                                                                                                                                                                              (1:400)

  Antibody                          Anti-mGluR1α                                        Frontier Institute, JAPAN                                        Frontier Institute: mGluR1a-GP-Af660; RRID:[AB_2571801](https://scicrunch.org/resolver/AB_2571801)   guinea pig polyclonal\
                                                                                                                                                                                                                                                              (1:500)

  Antibody                          Anti-Somatostatin                                   Peninsula Laboratories, USA                                      Peninsula Laboratories:T-4103.0050                                                                   rabbit polyclonal (1:2000)

  Antibody                          Anti-GABA~B1~(B17)                                  PMID: [11849296](https://www.ncbi.nlm.nih.gov/pubmed/11849296)                                                                                                        Rabbit polyclonal; against aa 901--960; (1:50)

  Antibody                          Anti-GABA~B1~(A25)                                  PMID: [16427742](https://www.ncbi.nlm.nih.gov/pubmed/16427742)                                                                                                        Rabbit polyclonal; against aa 857--960; (1:200)

  Antibody                          6 nm anti-Rabbit IgG (secondary)                    Jackson ImmunoResearch Europe, UK                                Jackson ImmunoResearch E:711-195-152                                                                 (1:30)

  Antibody                          12 nm anti-Guinea pig (secondary)                   Jackson ImmunoResearch Europe, UK                                Jackson ImmunoResearch E:706-205-148                                                                 (1:30)

  Antibody                          12 nm anti-Goat (secondary)                         Jackson ImmunoResearch Europe, UK                                Jackson ImmunoResearch E:705-205-147                                                                 (1:30)

  Antibody                          18 nm anti-Chicken (secondary)                      Jackson ImmunoResearch Europe, UK                                Jackson ImmunoResearch E:703-215-155                                                                 (1:30)

  Antibody                          3 nm anti-Guinea pig (secondary)                    Nanopartz, USA                                                   Nanopartz:CA11-3-FCDAGG-DIH-50--1                                                                    (1:800)

  Antibody                          Alexa Fluor 405,488,546 Anti-Rabbit (secondaries)   Invitrogen, UK                                                                                                                                                        (1:500)

  Other                             Alexa Fluor 647 Streptavidin                        Invitrogen, UK                                                   Invitrogen:S21374                                                                                    (1:500)

  Chemical compound, drug           NBQX                                                Abcam Biochemicals, UK                                           ab120046                                                                                             

  Chemical compound, drug           DL-AP5                                              Abcam Biochemicals, UK                                           ab120271                                                                                             

  Chemical compound, drug           Bicuculline                                         Abcam Biochemicals, UK                                           ab120108                                                                                             

  Chemical compound, drug           Gabazine                                            Abcam Biochemicals, UK                                           ab120042                                                                                             

  Chemical compound, drug           R-Baclofen                                          Abcam Biochemicals, UK                                           ab120325                                                                                             

  Chemical compound, drug           CGP-55845                                           Abcam Biochemicals, UK                                           ab120337                                                                                             

  Chemical compound, drug           SCH23,390                                           Tocris, UK                                                       0925/10                                                                                              

  Chemical compound, drug           Kainate                                             Tocris, UK                                                       0222/1                                                                                               

  Chemical compound, drug           Carbcahol                                           Abcam Biochemicals, UK                                           ab141354                                                                                             

  Software, algorithm               GraphPad Prism                                      GraphPad Software, USA                                                                                                                                                

  Software, algorithm               WinWCP                                              University of Strathclyde, UK                                                                                                                                         <http://spider.science.strath.ac.uk/sipbs/software_ses.htm>

  Software, algorithm               pClamp                                              Axon Instruments, USA                                                                                                                                                 

  Software, algorithm               MATLAB                                              Mathworks, USA                                                                                                                                                        

  Software, algorithm               StimFit                                             PMID: [24600389](https://www.ncbi.nlm.nih.gov/pubmed/24600389)                                                                                                        

  Software, algorithm               Fiji                                                                                                                                                                                                                      <http://fiji.sc>
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Electrophysiological experiments were performed in acute slices prepared from 17 to 26 day-old wild-type and transgenic Wistar rats expressing Venus/yellow fluorescence protein (YFP) under the vesicular GABA transporter (VGAT) promoter ([@bib75]) or 25--30 day old wild-type mice (C57/Bl6J~CRL~). For optogenetic experiments, 10--12 week-old SOM-Cre mice (Jackson Laboratories; Ssttm2.1(cre)Zjh/J; [@bib70]) were bilaterally injected with rAAVs containing Channelrhodopsin2 (ChR2) and tdTomato (tdTom) coding regions between inverted incompatible tandem loxP sites into the hippocampal CA1 area (coordinates from Bregma: 2 mm, 2 mm; 1.4 mm; 3 µl volume, 3 mins). Optogenetic experiments were performed 2--4 weeks following viral injection. Electron microscopy was performed on either 8-week-old male Wistar rats or 6-week-old male SOM-cre mice crossed with Ai32 (RCL-ChR2(H134R)/EYFP) transgenic mice (The Jackson Laboratory, stock number: 024109, Maine). Care and handling of the animals prior to and during the experimental procedures followed European Union and national regulations (German Animal Welfare Act; ASPA, United Kingdom Home Office) and all experiments were performed in accordance with institutional guidelines (Charité - Universitätmedizin Berlin; University of Freiburg, Freiburg, Germany), with permissions from local authorities (LaGeSo, Berlin, T-0215/11 LaGeSo; Freiburg, X14/11H and 35--9185.81/G-19/59).

Acute slice preparation {#s4-2}
-----------------------

Acute hippocampal slices were prepared and recordings performed as previously described [@bib12]. Briefly, rodents were decapitated (either directly or following cervical dislocation) and their brain rapidly dissected and chilled in semi-frozen carbogenated (95% O~2~/5% CO~2~) sucrose-substituted artificial cerebrospinal fluid (sucrose-ACSF, in mM: 87 NaCl, 2.5 KCl, 25 NaHCO~3~, 1.25 NaH~2~PO~4~, 25 glucose, 75 sucrose, 7 MgCl~2~, 0.5 CaCl~2~, 1 Na-Pyruvate, 1 Na-Ascorbate). Transverse hippocampal slices (300 or 400 μm thick) were cut on a vibratome (VT1200s, Leica, Germany) and stored submerged in sucrose-ACSF warmed to 35°C for at least 30 min and subsequently at RT. For recording of network oscillations, slices were stored in a liquid/gas interface chamber, which was perfused with normal ACSF (in mM: 125 NaCl, 2.5 KCl, 25 NaHCO~3~, 1.25 NaH~2~PO~4~, 25 glucose, 1 MgCl~2~, 2 CaCl~2~, 1 Na-Pyruvate, 1 Na-Ascorbate, pH 7.4) at 30--32°C from slicing until recording in order to maintain active oscillatory activity ([@bib31]).

Whole-cell patch-clamp recordings {#s4-3}
---------------------------------

For electrophysiological recordings, slices (300 μm thick) were placed in a submerged recording chamber, perfused with carbogenated ACSF at 10--12 ml/min and maintained at near physiological temperatures (32 ± 1°C) using an inline heater (Supertech Instruments, Pécs, Hungary). Slices were viewed under infrared Köhler illumination by means of an upright microscope (BX-50 or BX-51, Olympus, Hamburg, Germany or SliceScope, Scientifica, UK) with a 40x water-immersion objective lens (N.A. 0.8). Whole-cell patch-clamp recordings were accomplished using either an AxoPatch 200B or Multiclamp 700B amplifier (Molecular Devices, USA) and recording pipettes pulled from borosilicate glass capillaries (2 mm outer/1 mm inner diameter, Hilgenberg, Germany) on a horizontal electrode puller (P-97, Sutter Instruments, CA, USA). Pipettes were filled with intracellular solution (in mM: 120 K-Gluc, 20 KCl, 2 MgCl~2~, 10 EGTA, 10 HEPES, 2 Na~2~-ATP, 0.3 Na~2~-GTP, 1 Na~2~-Creatinine, 0.1% biocytin \[Invitrogen, UK\], pH 7.3, 290--310 mOsm) giving pipette resistances of 3--5 MΩ. All voltage-clamp recordings were performed at a holding potential of −65 mV and all current-clamp recordings were made from the resting membrane potential (V~M~). In voltage-clamp mode, series resistance (R~s~) was monitored, but not compensated. All signals were filtered online at 10 kHz using the built in 2-pole Bessel filter of the amplifiers, and digitized at 20 kHz (CED 1401, Cambridge Instruments, Cambridge, UK, NI USB-6212 BNC, National Instruments, Berkshire, UK, or Digidata 1550B, Axon Instruments, USA), using WinWCP (courtesy of John Dempster, Strathclyde University, Glasgow, UK; <http://spider.science.strath.ac.uk/sipbs/software_ses.htm>) or pClamp (Axon Instruments, USA). Data were analyzed offline using the open source Stimfit software package ([@bib29]) or MATLAB (Mathworks, USA).

We selected SOM-INs for recording on the basis of being YFP-positive cells with a soma at the *stratum* (*str.*) *oriens/alveus* border and with horizontal bipolar morphology. Recordings from CA1 PCs were obtained from YFP-negative neurons in the cell body layer. Cells were electrophysiologically characterized based on their response to a family of hyper- to depolarizing current injections (500 ms duration; −250 pA to 250 pA in 50 pA steps). Further confirmation of SOM-IN identity was based on the presence of a large voltage 'sag' in response to hyperpolarizing current steps and a non-adapting train of APs to depolarizing current. Neurons were rejected from further analysis when V~M~ \>-50 mV, if APs failed to overshoot 0 mV, initial R~s~ exceeded 30 MΩ, or R~s~ changed by \>20% in the course of the recording.

Characterization of presynaptic GABA~B~R-mediated inhibition {#s4-4}
------------------------------------------------------------

Pharmacologically isolated postsynaptic currents (EPSC and IPSC) were examined in the presence of either ionotropic receptor blockers bicuculline or gabazine (10 µM, both) for EPSCs or NBQX and APV (10 and 50 µM respectively) for IPSCs, which were added to the perfusing ACSF. To evoke synaptic responses, extracellular stimuli were delivered via a glass monopolar electrode (patch pipettes filled with 2 M NaCl, pipette resistance = 0.1 MΩ) placed 50--100 µm distal from the cell body in either the alveus (EPSCs) or *str. oriens* (IPSCs). PSCs were elicited using paired stimulus (2x stimuli at 20 Hz) repeated at 0.1 Hz. Stimulus intensity was titrated to give a monosynaptic response of approximately 100 pA (range of PSC amplitudes: 19 to 366 pA). Following 5 min of stable baseline, the GABA~B~R agonist R-baclofen was applied to the bath at 10 µM. In a subset of recordings, R-baclofen was added at increasing concentrations, in 5 min intervals, to assess the dose-response relationship. Following steady-state of baclofen wash-in, we removed baclofen and applied the GABA~B~R antagonist CGP-55,845 (5 µM) to the bath to selectively block GABA~B~Rs and confirm receptor specificity. The amplitude of PSCs was measured over a 10 ms window following the stimulus artifact and mean data are presented as the average of 12 traces normalized to baseline levels over the 2 min prior to baclofen wash-in. To assess the concentration dependence of postsynaptic R-baclofen effects, recordings were made from CA1 PCs, rather than from SOM-INs, given the very low-amplitude of postsynaptic GABA~B~R currents observed in these INs ([@bib14]).

Paired recordings from synaptically coupled CA1 PC-IN pairs {#s4-5}
-----------------------------------------------------------

To directly assess presynaptic GABA~B~R-mediated function at CA1 PC to SOM-IN synapses, we performed paired recordings between CA1 PCs and INs in *str. oriens*/alveus, as previously described ([@bib12]). Conditions were the same as those described above, albeit with a lower intracellular EGTA concentration (0.5 mM) to prevent excessive presynaptic Ca^2+^ buffering. Following characterization of intrinsic physiological responses of both pre- and postsynaptic neurons, trains of 10 APs (elicited by current pulses of 1--2 nA, 1 ms, 20 Hz) were delivered to the PC while recording the IN in voltage-clamp at −65 mV. A unitary synaptic connection was confirmed as a short latency (\<4 ms) EPSCs following the presynaptic APs detected in averages of 10 traces. If synaptic connectivity was not observed in the IN, the recording was abandoned, an outside-out patch formed, and a neighboring CA1 PC recorded. Once a synaptic connection was found, we recorded \>50 traces with unitary EPSCs from the interneurons elicited by APs evoked in the PCs by brief current pulses (1--2 nA, 1 ms) every 5 s, then applied 2 μM R-baclofen to the bath for 5 min, followed by application of CGP-55,845 (5 µM), without baclofen. The EPSC amplitude was measured from the preceding baseline as an average over a 0.4 ms window corresponding to the peak region of the synaptic responses within 10 ms from the start of the AP. Mean unitary EPSCs are shown and measured from at least 30 traces.

Optogenetic activation of SOM-INs {#s4-6}
---------------------------------

Whole-cell recordings were obtained from CA1 PCs in acute slices (300 μm thick) held at −70 mV in acute slices from mice expressing ChR2 and tdTom specifically in SOM-INs. IPSCs were evoked by pulses of blue light (473 nm; 2 ms; CoolLED system, UK) centered at the border of *str. radiatum* and *lacunosum-moleculare* repeated at 5 s intervals. Basal synaptic transmission was measured and the effect of R-baclofen (10 µM) was analyzed after 5 min of bath application. In a subset of experiments (4 out of 6), CGP 55845 (5 µM), without baclofen, was subsequently bath applied and the prior effect of baclofen was fully reversed. In a subset of recordings, 10 µM SCH-23,390 was preapplied to the bath, after which first baclofen and then CGP were co-applied with SCH-23,390. Data were obtained from averages of 30--50 traces except for the figure showing the time course of drug effects.

Generation of network oscillations and field potential recordings {#s4-7}
-----------------------------------------------------------------

To preserve a larger intact local network, thicker, 400 µm acute hippocampal slices were prepared (as above) in either the transverse (gamma oscillations) or longitudinal plane (theta oscillations) ([@bib25]), then stored in a liquid/gas interface chamber. For theta oscillations, slices were moved from the interface chamber, into a submerged chamber perfused with ACSF containing 50 µM carbachol at a rate of 10--12 ml/minute. An extracellular recording electrode made of a patch pipette filled with ACSF was carefully placed in proximal *str. radiatum* and the field response recorded. For gamma oscillations slices were transferred to the submerged recording chamber and a pressure application ('puff') pipette containing 2 mM kainate was placed in the distal *str. radiatum.* Puffs of kainate (10 psi, 20 ms, repeated at 1 min intervals) were applied to the slice, which invariably resulted in gamma oscillations in the field. Once a stable oscillation was confirmed a SOM-IN was recorded from *str. oriens* and a minimum of 5 min of theta or 5 kainate puffs were collected following recovery of the oscillation to the previous state. Given the EC~50~ of R-baclofen being \~1 µM at presynaptic GABA~B~Rs, we applied 2 µM R-baclofen to the bath and following wash in (2 mins) a further 5 min of oscillation data were collected. In a subset of recordings, to facilitate AP discharge, a depolarizing bias current 10 pA below rheobase was applied to the recorded neuron. In a further subset of recordings a second puff pipette filled with 2 mM baclofen dissolved in 150 mM NaCl was placed in *str. oriens* proximal to the recorded IN (\<100 µm). First 3 kainate puffs alone were applied to collect control data, then 3 puffs where baclofen puff preceded the kainate puff by 100 ms were applied to examine the effects of GABA~B~R activation. In some recordings CGP (5 µM) was applied following R-baclofen to confirm the receptor specificity.

Prior to analysis, all field recordings were band-pass filtered using a Butterworth-filter at 4--20 Hz (Theta) or 30--200 Hz (Gamma). Peak oscillatory power was measured using fast-Fourier transform (FFT)-based spectral analysis (Spike2 software, CED, Cambridge, UK). Peak frequency and power were measured across 5 min of theta activity following carbachol wash in or during the initial 10 s of gamma activity evoked by the kainate puff. Spike triggered averages were produced using a custom MATLAB script, over either a 150 ms (Theta) or 25 ms window (Gamma) (code available on GitHub: <https://github.com/imrevida/eLife-Booker-2020-MatlabCode>; [@bib79]; copy archived at <https://github.com/elifesciences-publications/eLife-Booker-2020-MatlabCode>). The relative phase of each AP was determined according to the Hilbert transform and plotted with respect to the full cycle of each oscillation. Mean AP frequency was measured as the number of spikes observed over the respective recording window.

Visualization, imaging and reconstruction of the recorded neurons {#s4-8}
-----------------------------------------------------------------

Immunocytochemistry was performed to identify recorded neurons ([@bib12]). Following experiments, slices were fixed in 4% paraformaldehyde diluted in 0.1 M PB overnight (O/N) at 4°C. Slices were rinsed in PB, then phosphate-buffered saline (PBS; 0.025 M PB and 0.9% NaCl) and blocked with 10% normal goat serum (NGS) with 0.3--0.5% TritonX-100 and 0.05% NaN~3~ diluted in PBS for 1 hr at RT. Slices were then incubated for 48--72 hr in a PBS solution containing 5% NGS, 0.3--0.5% TritonX-100 and 0.05% NaN~3~ and primary antibodies against SOM (rabbit polyclonal, 1:2000, Peninsula Laboratories, USA), at 4°C. Slices were subsequently rinsed extensively in PBS for an hour and then incubated with fluorescently conjugated secondary antibodies raised against rabbit (Goat-anti rabbit AlexaFluor 405, 488 or 546; 1:500, Invitrogen, Dunfermline, UK) as well as fluorescently conjugated streptavidin (AlexaFluor 647; 1:500, Invitrogen) in a PBS solution containing 3% NGS, 0.1% TritonX-100% and 0.05% NaN~3~ O/N at 4°C. Slices were rinsed in PBS, then PB, and mounted on glass slides with a polymerizing mounting medium (Fluoromount-G, Southern Biotech, AL, USA) and cover-slipped. Filled neurons were imaged with a laser scanning confocal microscope (FluoView 1000, Olympus) under a 20x (N.A 0.75) objective and z-axis stacks of images (2048 × 2048 pixels, at 1 μm axial steps) collected to allow identification of somatodendritic and axonal arborizations. To assess immunoreactivity of the recorded cells the somata and proximal dendrites of neurons were imaged with a silicon-immersion 60x (N.A. 1.3) objective lens and either single confocal images or stacks of 5--10 images at 1 µm axial steps were taken. Selected, representative cells were reconstructed off-line from 20x magnification image stacks digitally stitched using semi-automatic analysis software (Simple Neurite Tracer plug-in for the FIJI software package, <http://fiji.sc>) ([@bib49]).

Sodium dodecyl sulfate-digested freeze-fracture replica immunolabeling (SDS-FRL) {#s4-9}
--------------------------------------------------------------------------------

To determine the distribution pattern and density of GABA~B~Rs on presynaptic boutons contacting SOM-INs and axon terminals of the INs, the GABA~B1~ subunit was detected with SDS-FRL as previously described ([@bib15]). Male mice (6-week-old, n = 3) in which SOM-INs selectively expressed ChR2-YFP fusion protein were derived from crossing SOM-Cre and Ai32 transgenic mice. These mice and male Wistar rats (8-week-old, n = 2) were sedated with isoflurane and then terminally anesthetized with pentobarbital (80 mg/kg for mice and 50 mg/kg for rats, intraperitoneally). Animals were then transcardially perfused with 0.9% NaCl for 1 min followed by a fixative containing 1% paraformaldehyde and 15% saturated picric acid in 0.1 M PB (pH 7.4) for 12 min. Hippocampal slices (130 µm) were cut on a vibratome (VT 1000, Leica, Vienna, Austria) and cryoprotected with 30% glycerol in 0.1 M PB O/N at 4°C. Blocks containing all layers of the CA1 area were trimmed from the slices and frozen under high-pressure (HPM 100, Leica). The frozen samples were fractured at −140°C and the fractured facets were coated with carbon (5 nm), platinum-carbon (2 nm) and an additional layer of carbon (18 nm) in a freeze-fracture replica machines (ACE 900, Leica or BAF 060, BAL-TEC, Lichtenstein). Replicas were digested at 60°C in a solution containing 2.5% SDS and 20% sucrose diluted in 15 mM Tris buffer (TB, pH 8.3) for 48 hr followed by 37°C for 18 hr, washed in washing buffer comprising 0.05% bovine serum albumin (BSA, Roth, Germany) and 0.1% Tween 20 in 50 mM Tris-buffered saline (TBS) and then blocked in a solution containing 5% BSA and 0.1% Tween 20 in TBS for 1 hr at RT. Afterwards, replicas were incubated at 15°C for 2 days in the following mixtures of primary antibodies in a solution containing 1% BSA and 0.1% Tween 20 made up in TBS: (i) GABA~B1~ (B17, rabbit, 10 µg/ml; [@bib39]) or A25, rabbit, 5 µg/ml; [@bib22]), green fluorescence protein (GFP-1010, chicken, 0.4 µg/ml, Aves Labs, Oregon) and Ca~v~2.1 (Guinea pig, 4 µg/ml, Frontier Institute, Hokkaido, Japan; [@bib5]) or (ii) GABA~B1~, GFP and vesicular glutamate transporter 1 (VGluT1, goat, 0.5 µg/ml, Frontier Institute, Hokkaido; [@bib43]) or (iii) GABA~B1~, GFP and vesicular GABA transporter (VGAT, Guinea pig, 4.5 µg/ml, Frontier Institute, Hokkaido; [@bib5]) or (iv) GABA~B1~, GFP, VGluT1 and metabotropic glutamate receptor 1α-subunit (mGluR1α, Guinea pig, 0.4 µg/ml, Frontier Institute, Hokkaido; [@bib14]). Replicas were washed in washing buffer then reacted with 6 nm, 12 nm and 18 nm gold particle-conjugated secondary antibodies (1:30, Jackson ImmunoResearch Europe, Cambridgeshire) or with the aforementioned antibodies together with 3 nm gold particle-conjugated secondary antibody (1:800, Nanopartz, Colorado) O/N at 15°C. Finally, replicas were washed in TBS then distilled water and mounted on Formvar-coated 100-mesh grids.

Electron microscopy {#s4-10}
-------------------

Replicas were analyzed with an electron microscope (Zeiss Leo 912 omega, Carl Zeiss, Oberkochen, Germany). All antibodies target intracellular epitopes of proteins, therefore, immunoreactivity can be observed on the protoplasmic face (P-face) of the plasma membrane. Boutons contacting YFP-positive dendritic shafts of INs in *str. oriens-alveus* and YFP-positive axon terminals of INs in *str. lacunosum-moleculare* were sampled. Densely spiny CA1 PC dendrites in *str. radiatum*, YFP-positive dendritic shafts of SOM-INs in *str. oriens-alveus*, and YFP-negative boutons of putative PCs in *str. oriens* were used as a control for GABA~B1~ labeling.

Chemicals and pharmacology {#s4-11}
--------------------------

All chemicals were obtained from either Sigma Aldrich (Munich, Germany) or Carl Roth (Karlsruhe, Germany). Biocytin was obtained from Life Technologies (Dunfermline, UK). Pharmacological agents were obtained from Abcam Biochemicals (Cambridge, UK) or Tocris Bioscience (Bristol, UK). Drugs were stored as 1000-fold concentrated stocks at −80°C until used. Working solutions were prepared fresh on the day in normal ACSF at final concentrations given in the text.

Statistical analysis {#s4-12}
--------------------

Statistical analysis was performed with Graphpad Prism (GraphPad Software, CAUSA). Analysis of unpaired data was performed with Mann-Whitney U tests. Group data were compared with one-way ANOVA tests, combined with Holm-Sidak post-tests. Paired group data were analyzed with one-way repeated measures ANOVA. Data are shown as mean ± SEM throughout. Statistical significance was assumed if p\<0.05.
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**Acceptance summary:**

The findings of this study significantly advance our understanding of the modulation of synaptic activity in the context of hippocampal network function. Using freeze-fracture replica immunolabelling, the authors provide high quality anatomical support for modulation of somatostatin interneurons by GABA~B~ receptors, and combine this with whole cell electrophysiological recordings and optogenetics to probe the role of these receptors in hippocampal function in vitro.

**Decision letter after peer review:**

Thank you for submitting your article \"Presynaptic GABA~B~ receptors functionally uncouple somatostatin interneurons from the active hippocampal network\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Laura Colgin as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Francesco Ferragutti (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors of this manuscript have investigated whether the activation of presynaptic GABA~B~ receptors can modulate the synaptic inputs onto the SOM+ hippocampal interneurons as well as their output synapses. Using pharmacological tools the authors unequivocally demonstrated that GABA~B~ receptors are in a position to critically influence the transmitter release at both the input and output synapses of SOM+ interneurons. The findings of this study are of high scientific interest as they significantly advance our understanding of the modulation of synaptic activity by GABA~B~ receptors at the SOM interneuron feedback hippocampal microcircuit. Most of the experiments described in this paper are very well performed. Both the anatomical localization of GABA~B~ receptors using the freeze-fracture replica immunolabelling approach, a technique mastered by the Kulik\'s lab, and the functional characterization of the influence of GABA~B~ receptors on the SOM interneuron feedback microcircuit by means of whole-cell recordings and in vitro optogenetics are of very high quality. In the last part of the paper, the authors provide indirect evidence for a network effect that is dependent on GABA~B~ receptors influence on SOM+ cells: they propose that specific activation of presynaptic GABA~B~ receptors could have an impact on the coupling of SOM+ interneuron spiking during network oscillations induced in slice preparations. However, result show that with "global" GABA~B~ activation SOM+ IN spiking was substantially reduced in a way that was correlated with the decrease in oscillation power. This last finding regarding specific network effects needs stronger experimental support.

Essential revisions:

1\) Bath application of 2 µM baclofen caused a marked reduction in the peak amplitude of network oscillations as well as in the firing rate of OLM+ neurons. Based on the present findings, GABA~B~ receptors can reduce the ESPCs onto SOM+ interneurons, leading to de-coupling of their firing from the ongoing oscillations, as proposed by the Authors. However, based on these results it is hard to conclude that presynaptic GABA~B~ receptors are mainly responsible for de-coupling of SOM+ IN activity from the oscillations. Many in vitro and in vivo studies have shown that the IN firing is primarily driven by phasic EPSCs (i.e. synchronous discharge of pyramidal cells) during oscillatory activities. Therefore, GABA~B~ receptor activation, impacting both the fast spiking interneuron and the pyramidal cell operation (Booker et al., 2013, 2017), can first cause a reduction in the oscillation power by altering the oscillogenesis, which leads to the de-synchronization of EPSCs, and therefore to the suppression of phase-coupled spiking in any interneuron types. Using the applied methods, comparing the features of spiking and oscillation in three discrete time points, it is hard to distinguish between these two scenarios, which may actually work in parallel. This tentative result requires additional experimental evidence. One experimental approach that might provide more direct evidence for the decoupling hypothesis (we are sure the authors will have many other ideas) is the following: Local application of baclofen into the surrounding of the SOM IN while spiking is monitored. This approach can minimize the effect of the baclofen at the postsynaptic GABA~B~ receptors on the pyramidal cells, i.e. the oscillogenesis will not be impaired. Yet, synchronous EPSCs from the PCs could be reduced by locally applied baclofen via presynaptic GABA~B~ receptors, leading to a reduction in EPSC magnitude. If this effect is large enough, then activation of presynpatic GABA~B~ receptors could suppress the phasic excitation received by SOM INs without affecting the gamma oscillation globally. Under these circumstances, SOM IN spiking should be uncoupled from the on-going oscillation, supporting the original claim.

Overall, the authors conclusions on this point do not adequately consider that in their experimental paradigm the activation of presynaptic GABA~B~ receptors on glutamatergic and GABAergic terminals innervating SOM interneurons and on terminals from these interneurons onto pyramidal cells occurred simultaneously, a situation highly unlikely in vivo.

Further, activation of GABA~B~ receptors at presynaptic GABAergic terminals (presumably originating from VIP/CR interneurons) onto SOM interneurons should: i) reduce quite effectively the release of GABA (also in view of their high density at these terminals) from VIP/CR interneurons and consequently also the spillover onto glutamatergic synapses, hence, lifting, at least in part, the heterosynaptic inhibition onto feedback inputs from pyramidal cells; ii) lead to disinhibition of SOM interneurons; iii) increase their gating of entorhinal inputs. This would be quite different from a functional uncoupling.

2\) SOM+ interneurons in the CA1 hippocampus are diverse as they belong to at least two categories: OLM cells and GABAergic projecting neurons, often innervating the medial septum. Would it be possible to split at least a portion of the recorded interneurons into the two groups and compare whether the inputs of these two interneuron types are controlled similarly or distinctly by presynaptic GABA~B~ receptors? The categorization can be based on the morphological features, including the axon arborization, the morphology of the dendrites, the location of the axon initial segments (axon initiates usually from the dendrites in case of OLM cells, whereas the axon initial segment of projecting neurons originates from the soma), and/or the single cell properties such as the \'sag\' characteristics (Zemankovics et al., 2010). Comparison performed even on a subset of interneurons may provide some valuable insights how the inputs onto these functionally distinct inhibitory cells are controlled via GABA~B~ receptors.

3\) The authors claim a different sensitivity (EC50) between presynaptic (1.1 µM) and postsynaptic (4.3 µM) GABA~B~ receptors to baclofen. However, based on the confidence intervals deduced from the dose response curves shown in Figure 1D, I would conclude that there is no difference in the EC50 between pre- and post-synaptic GABA~B~ receptors. The claim that a pharmacological difference exists between these two GABA~B~ receptor pools must be removed, and, likewise, any statement that a certain concentration of baclofen (e.g. 2 µM) would preferentially activates one of the pools.

4\) In subsection "GABA~B~R Subunits are Expressed at Presynaptic Boutons Forming Synapses Onto SOM-INs", it is mentioned that the density of GABA~B1~ labelling is higher in VGluT1-negative boutons in comparison with VGluT1-positive boutons. Was it quantified? If so, how did it compare with the data shown in Figure 4D?

5\) The manuscript needs additional editing in order to fully understand the text. There are many sentences that are difficult to understand, and there are some apparent grammatical/syntactic errors.

a\) Supplementary Figure 1. Related to Figure 1 has a wrong legend.

There are two figures called: \"Supplementary Figure 1\" and \"Supplementary Figure 1. Related to Figure 1\". They have the same legend but they have different images.

For his reason it is very difficult to read the section about EM.

-- Paragraph two of subsection "GABA~B~R Subunits are Expressed at Presynaptic Boutons Forming Synapses Onto SOM-INs": (data not shown), please show this data.

b\) Statistical analysis: In the methods, Mann-Whitney or Wilcoxon tests were used. This contrasts with the results, in which it never seems to be mentioned Wilcoxon test was used. This is especially important for the data in Figure 1F for PPR and later for experiments with SCH. It is incorrect to say that \"... lower than the control IPSCs in the group without SCH application, albeit not significantly different....\". Mann-Whitney test was used to check statistics. However, this is a paired recording and you should use e.g. Wilcoxon test.

c\) Does the application of Kir3 channel blocker influence IPSC amplitude, input resistance, and/or whole-cell currents in PC and SOM? If Kir3 blocker affects these parameters maybe you should consider reverse experiments (SCH after baclofen)? Would you see the same effect as during experiments with baclofen after SCH? Do you mean by your experiments that baclofen does not activate postsynaptic GABA~B~ receptors onto PC cells?

d\) What is the effect of baclofen on the whole-cell current in SOM neurons and PC cells?

6\) Major concerns for methods:

-- The rationale for two different approaches to incorporate ChR2-YFP proteins into SOM INs is not clear.

What was the reason for virus injections vs. Ai32 mice? Were there any differences?

Subsection "Acute slice preparation": \"...slices (300 or 500)...\", but in the legend of Figure 7 indicates 400.

-- Subsection "Characterization of presynaptic GABA~B~R-mediated inhibition": The response was about 100 pA (range of intensities: 19-366 pA). It is unclear what \"intensities\" is related to (the amplitude or the stimulus intensity?). How is the amplitude related to the maximal response? PPR is strongly dependent on the stimulus strength; the effect of baclofen might be also dependent on the stimulation intensity. Could you comment this?

-- Subsection "Paired recordings from synaptically coupled CA1 PC-IN pairs": Could you explain why you use two different concentration of EGTA: 10 and then 0.5 mM?

7\) Discussion:

Several sentences are unclear. Please revise for lucidity: Paragraph one and two: What is \"them\" related to? SOM-Ins or PCs or both?

-- Figure 5: E: it is unclear how many cells are there in fact. If points are overlaid, please arrange them in the way you use in Figure 4.

-- Figure 7: Consider different, more distinct colors, clarify legend.
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Author response

> Essential revisions:
>
> 1\) Bath application of 2 µM baclofen caused a marked reduction in the peak amplitude of network oscillations as well as in the firing rate of OLM+ neurons. Based on the present findings, GABA~B~ receptors can reduce the ESPCs onto SOM+ interneurons, leading to de-coupling of their firing from the ongoing oscillations, as proposed by the Authors. However, based on these results it is hard to conclude that presynaptic GABA~B~ receptors are mainly responsible for de-coupling of SOM+ IN activity from the oscillations. Many in vitro and in vivo studies have shown that the IN firing is primarily driven by phasic EPSCs (i.e. synchronous discharge of pyramidal cells) during oscillatory activities. Therefore, GABA~B~ receptor activation, impacting both the fast spiking interneuron and the pyramidal cell operation (Booker et al., 2013, 2017), can first cause a reduction in the oscillation power by altering the oscillogenesis, which leads to the de-synchronization of EPSCs, and therefore to the suppression of phase-coupled spiking in any interneuron types. Using the applied methods, comparing the features of spiking and oscillation in three discrete time points, it is hard to distinguish between these two scenarios, which may actually work in parallel. This tentative result requires additional experimental evidence. One experimental approach that might provide more direct evidence for the decoupling hypothesis (we are sure the authors will have many other ideas) is the following: Local application of baclofen into the surrounding of the SOM IN while spiking is monitored. This approach can minimize the effect of the baclofen at the postsynaptic GABA~B~ receptors on the pyramidal cells, i.e. the oscillogenesis will not be impaired. Yet, synchronous EPSCs from the PCs could be reduced by locally applied baclofen via presynaptic GABA~B~ receptors, leading to a reduction in EPSC magnitude. If this effect is large enough, then activation of presynpatic GABA~B~ receptors could suppress the phasic excitation received by SOM INs without affecting the γ oscillation globally. Under these circumstances, SOM IN spiking should be uncoupled from the on-going oscillation, supporting the original claim.

We agree that bath application of baclofen likely attenuates presynaptic release of both GABA and glutamate in the wider network, plausibly explaining the reduction in gamma and theta oscillation power observed over the spectra and peak power plots (Figure 7B and F). To address these concerns, we followed the suggestion of the reviewers and performed dedicated experiments in which we focally applied baclofen in the proximity of a recorded SOM-IN in *str. oriens* (\<100 µm from the IN somata) during kainate-induced gamma oscillations (Results and new Figure 7---figure supplement 2). These data show that there is no change to the gamma power induced by kainate application to *str. radiatum* when baclofen is focally applied. Nevertheless, focal baclofen application produces a strong reduction in SOM-IN AP discharge, supporting our hypothesis of an uncoupling of the INs from the network by presynaptic GABA~B~R activation.

We performed the new experiments in mouse slices, whereby we could also show that the strong presynaptic inhibition of EPSCs onto SOM-INs is not species specific (Results and new Figure 1---figure supplement 1), and that gamma power, as well as, the discharge of the INs are strongly attenuated by bath application of baclofen in mice, too (Results and new Figure 7---figure supplement 1).

Together these new data show that local activation of GABA~B~ receptors at axon terminals onto SOM-INs during ongoing gamma oscillations is sufficient to uncouple and silence this IN population and that this property is shared between the two rodent species.

> Overall, the authors conclusions on this point do not adequately consider that in their experimental paradigm the activation of presynaptic GABA~B~ receptors on glutamatergic and GABAergic terminals innervating SOM interneurons and on terminals from these interneurons onto pyramidal cells occurred simultaneously, a situation highly unlikely in vivo.

We agree with the reviewer that GABA activating of GABA~B~Rs in the *str oriens*, where SOM-INs soma and dendrites and their input synapses are localized, *versus* the str. l-m., where their axons terminate, is likely to originate from distinct sources and therefore occur independently. Nevertheless, network mechanisms may coordinate these sources and extracellular GABA levels can surge simultaneously in the two layers under certain conditions.

We have added a sentence to the Discussion to raise this point.

> Further, activation of GABA~B~ receptors at presynaptic GABAergic terminals (presumably originating from VIP/CR interneurons) onto SOM interneurons should: i) reduce quite effectively the release of GABA (also in view of their high density at these terminals) from VIP/CR interneurons and consequently also the spillover onto glutamatergic synapses, hence, lifting, at least in part, the heterosynaptic inhibition onto feedback inputs from pyramidal cells; ii) lead to disinhibition of SOM interneurons; iii) increase their gating of entorhinal inputs. This would be quite different from a functional uncoupling.

This is indeed a very interesting point; however, we don't see a way to selectively activate presynaptic receptors at GABAergic input synapses onto SOM-INs. One pertinent point is that it is unclear what are the main sources of GABA for the activation of presynaptic GABA~B~R at these synapses. One possibility is that GABA is released from VIP/CR INs, as the reviewer suggests. Alternatively, other IN types, most notably Ivy cells, but also Bistratified cells or even SOM-INs themselves, could be the source of GABA in this layer. In our experimental paradigm (including the newly performed experiments suggested by the reviewer), we assumed that the increase in extracellular GABA concentration occurs due to spillover (mimicked by baclofen application) and thereby produces heterosynaptic inhibition. Under these conditions reduced GABAergic transmission onto SOM-INs matches the reduction of glutamatergic transmission in line with a network uncoupling, rather than leading to disinhibition of the INs.

> 2\) SOM+ interneurons in the CA1 hippocampus are diverse as they belong to at least two categories: OLM cells and GABAergic projecting neurons, often innervating the medial septum. Would it be possible to split at least a portion of the recorded interneurons into the two groups and compare whether the inputs of these two interneuron types are controlled similarly or distinctly by presynaptic GABA~B~ receptors? The categorization can be based on the morphological features, including the axon arborization, the morphology of the dendrites, the location of the axon initial segments (axon initiates usually from the dendrites in case of OLM cells, whereas the axon initial segment of projecting neurons originates from the soma), and/or the single cell properties such as the \'sag\' characteristics (Zemankovics et al., 2010). Comparison performed even on a subset of interneurons may provide some valuable insights how the inputs onto these functionally distinct inhibitory cells are controlled via GABA~B~ receptors.

We have examined the morphology of the recorded and immunocytochemically-identified SOM-INs. Of a total of 63 rat SOM-INs, 25 cells possessed an axon projecting to the *str. lacunosum-moleculare,* 2 INs had bistratified axons in *str. radiatum* and *oriens*, and 4 had axons confined to *str. oriens* only. The remaining INs either had axons cut close to the soma (8 cells) or were not sufficiently filled to allow morphological identification (24 cells). Of the 8 cells with cut axon, 7 had the axon clearly emerging from a primary dendrite, and only 1 had an axon originating from the soma. As such, we believe that our data reflect an enriched population of OLM cells. We have now included the above morphological data in the Results text.

> 3\) The authors claim a different sensitivity (EC50) between presynaptic (1.1 µM) and postsynaptic (4.3 µM) GABA~B~ receptors to baclofen. However, based on the confidence intervals deduced from the dose response curves shown in Figure 1D, I would conclude that there is no difference in the EC50 between pre- and post-synaptic GABA~B~ receptors. The claim that a pharmacological difference exists between these two GABA~B~ receptor pools must be removed, and, likewise, any statement that a certain concentration of baclofen (e.g. 2 µM) would preferentially activates one of the pools.

We appreciate the reviewers concerns and have removed the data concerning pharmacological differences from Figure 1 and from the Results.

> 4\) In subsection "GABA~B~R Subunits are Expressed at Presynaptic Boutons Forming Synapses Onto SOM-INs", it is mentioned that the density of GABA~B1~ labelling is higher in VGluT1-negative boutons in comparison with VGluT1-positive boutons. Was it quantified? If so, how did it compare with the data shown in Figure 4D?

The immunoparticle density for GABA~B1~ was initially quantified in VGluT1+/VGAT- excitatory and VGluT1-/VGAT+ inhibitory terminals obtained from mouse brains, because dendrites of SOM-INs selectively expressed ChR2-YFP fusion protein, which enabled us to analyze boutons making synapses on identified dendritic shafts of neurons of interest. The surface density of the receptor subunit in rat samples has also been determined, but using another GABA~B1~ subunit-specific antibody (A25), due to the limited availability of B17 antibody. Because the intensity of immunolabelling was generally weaker with A25 than with B17, the absolute values cannot be directly compared. However, the relative density of GABA~B1~ in the two groups of terminals was the very similar: mouse inhibitory terminals possess 2.5-fold higher mean density of GABA~B1~ than excitatory boutons (43.00 particles/µm^2^*vs*. 17.37 particles/µm^2^, p=0.0001, Mann-Whitney test; see also Results), whereas rat inhibitory boutons show 2.7-fold higher mean density for the subunit than excitatory terminals (30.03 particles/µm^2^*vs*. 11.00 particles/µm^2^, p=0.0002, Mann-Whitney U test). Please also see the bar graphs in [Author response image 1](#respfig1){ref-type="fig"}.

![Summary bar charts of the surface densities of immunogold particles for GABA~B1~ subunit in excitatory and inhibitory axon terminals forming synapses onto SOM-IN dendrites in the mouse (left) and the rat hippocampus (right) detected using the B17 and A25 primary antibodies, respectively (see Materials and methods for further detail).\
Superimposed open circles represent density values from individual boutons.](elife-51156-resp-fig1){#respfig1}

> 5\) The manuscript needs additional editing in order to fully understand the text. There are many sentences that are difficult to understand, and there are some apparent grammatical/syntactic errors.

We apologize for typographical and syntactic errors. We have addressed all highlighted problems and made effort to eliminate any further mistakes in the revised version.

> a\) Supplementary Figure 1. Related to Figure 1 has a wrong legend.
>
> There are two figures called: \"Supplementary Figure 1\" and \"Supplementary Figure 1. Related to Figure 1\". They have the same legend but they have different images.
>
> For his reason it is very difficult to read the section about EM.

We thank the reviewer flagging this up and apologize for the ambiguity. This has been corrected in the revised version. Please note that due to the inclusion of new figures the supplemental figures were also renumbered.

> -- Paragraph two of subsection "GABA~B~R Subunits are Expressed at Presynaptic Boutons Forming Synapses Onto SOM-INs": (data not shown), please show this data.

We have now included representative images in a new Figure 3---figure supplement 2 to illustrate the statement made in the Results text.

> b\) Statistical analysis: In the methods, Mann-Whitney or Wilcoxon tests were used. This contrasts with the results, in which it never seems to be mentioned Wilcoxon test was used. This is especially important for the data in Figure 1F for PPR and later for experiments with SCH. It is incorrect to say that \"... lower than the control IPSCs in the group without SCH application, albeit not significantly different....\". Mann-Whitney test was used to check statistics. However, this is a paired recording and you should use e.g. Wilcoxon test.

We have thoroughly checked and revised the Materials and methods and the Results to reflect the tests employed. We, in fact, did not use the Wilcoxon test, as the final data was better reflected by a 1-way repeated-measures ANOVA to account for within cell effects -- as in Figure 1D-G. For post-hoc tests, we uniformly used the Holm-Sidak test, adjusted for multiple comparisons.

With regard to the specific example the comparison made here is between the IPSC recorded under control conditions in one group of cells and the IPSC elicited in the presence of SCH in another group of cells. As such this is not a paired analysis, and for this non-normally distributed data we believe the Mann-Whitney test is more appropriate.

> c\) Does the application of Kir3 channel blocker influence IPSC amplitude, input resistance, and/or whole-cell currents in PC and SOM? If Kir3 blocker affects these parameters maybe you should consider reverse experiments (SCH after baclofen)? Would you see the same effect as during experiments with baclofen after SCH? Do you mean by your experiments that baclofen does not activate postsynaptic GABA~B~ receptors onto PC cells?

The aim of applying of SCH was to eliminate potential shunting effects due to postsynaptic GABA~B~ receptor activation mediated by Kir3 channels. As we had stated in the Results before, SCH application blocks a large portion of the baclofen-induced postsynaptic Kir3 current in CA1 PCs. Nevertheless, the reduction in the amplitude of the IPSCs in response to baclofen application in the presence and absence of SCH was comparable, indicating that the reduced transmission was primarily reflecting a presynaptic inhibitory effect.

To address the issue raised by the reviewer, we have included an additional figure (new Figure 5---figure supplement 1) summarizing the effects of baclofen, CGP and SCH on whole-cell currents in CA1 PCs. Consistent with the lack of tonic postsynaptic GABA~B~-mediatedcurrents in PCs (new Figure 5---figure supplement 1B; see also Degro et al., 2015), we haven't noticed any effect of SCH on whole-cell current or input resistance in PCs. Finally, IPSCs amplitudes, even if they tended to be smaller in our sample of cells recorded in the presence of SCH, were not significantly different from the control sample (see Figure 5C and D, and the relevant section in the Results).

Regarding the effects in SOM-INs, as we have shown previously, GABA~B~Rs on SOM-IN dendrites only minimally activate Kir3 channels (Booker et al., 2018); therefore we would not expect any large impact of SCH application in these cells in the absence or presence of baclofen. A thorough characterization of the postsynaptic interactions of baclofen and SCH in PCs and SON-INs, in our view, would be beyond the scope of the present study.

> d\) What is the effect of baclofen on the whole-cell current in SOM neurons and PC cells?

We addressed this question in our previous study (Booker et al., 2018), in which we showed that pharmacological activation of GABA~B~Rs in the absence of GABAergic and glutamatergic synaptic inputs (DL-AP5, CNQX, and Bicuculline) leads to minimal post-synaptic currents. A comment to this effect is included now at the beginning of the Results. Summary data on whole-cell currents measured in baclofen, SCH and CGP in CA1 PCs has been added as a new Figure 5---figure supplement 1 to the revised version.

> 6\) Major concerns for methods:
>
> -- The rationale for two different approaches to incorporate ChR2-YFP proteins into SOM INs is not clear.
>
> What was the reason for virus injections vs. Ai32 mice? Were there any differences?

The physiological and anatomical investigations were not simultaneously performed and at the time of the optogenetic experiments Ai32 animals were not yet available for breeding.

However the distinct approaches seemed to be functionally favourable for the experiments as the viral injection enabled a focal transfection of SOM-INs and supported photostimulation of a lower number of local axons synapsing onto the recorded CA1 PCs, whereas the SOM-Cre x Ai32 animals facilitated an efficient SDS-FRIL-EM characterization of SOM-INs input and output synapses.

> Subsection "Acute slice preparation": \"...slices (300 or 500)...\", but in the legend of Figure 7 indicates 400.

Thank you for pointing out this inconsistency. This should have read 400 µm for all in vitro oscillation experiments, as we used slightly thicker slices to preserve a larger intact local network. We used standard 300 µm acute slices for all other experiments as these provide better optics for cell identification, whilst keeping most cellular processes intact. This ambiguity has been corrected at all the relevant locations in the Materials and methods.

> -- Subsection "Characterization of presynaptic GABA~B~R-mediated inhibition": The response was about 100 pA (range of intensities: 19-366 pA). It is unclear what \"intensities\" is related to (the amplitude or the stimulus intensity?). How is the amplitude related to the maximal response? PPR is strongly dependent on the stimulus strength; the effect of baclofen might be also dependent on the stimulation intensity. Could you comment this?

This was an inappropriate choice of wording, as it should have been "PSC amplitude" and not "intensity". This has been corrected.

Regarding the relationship between PSC amplitude and Baclofen response or PPR, we did not observe a statistically significant effect of EPSC or IPSC amplitude on either property. Please see the plots in [Author response image 2](#respfig2){ref-type="fig"}.

![Dependence of baclofen mediated presynaptic inhibition and paired-pulse ratio on the EPSC and IPSC ampli-tudes.\
(**A**) Baclofen-induced presynaptic inhibition of EPSCs (filled circles) and IPSCs (open circles) plotted as a function of PSC amplitude. Based on a linear regression analysis, neither EPSCs (F(d.f. 1,13) = 2.5, p = 0.14, F-test, solid line) nor IPSC s(F(d.f. 1,7) = 0.00002, p = 0.99, F-test, dashed line) displayed a dependence of the bac-lofen response on the PSC amplitudes. (**B**) EPSC and IPSC amplitude effect on the degree of paired pulse ratio observed. Based on a linear regression analysis, neither EPSCs (F(d.f. 1,13) = 2.1, p = 0.17, F-test) nor IPSC s(F(d.f. 1,7) = 2.0, p = 0.20, F-test) displayed a strong interaction of PPR and synaptic strength.](elife-51156-resp-fig2){#respfig2}

> -- Subsection "Paired recordings from synaptically coupled CA1 PC-IN pairs": Could you explain why you use two different concentration of EGTA: 10 and then 0.5 mM?

A lower concentration of EGTA was used for presynaptic experiments to prevent excessive Ca^2+^ buffering saturating endogenous buffering mechanisms. A clarification has been added to the Materials and methods.

> 7\) Discussion:
>
> Several sentences are unclear. Please revise for lucidity: Paragraph one and two: What is \"them\" related to? SOM-Ins or PCs or both?

We have reworded these sentences and hope that we have addressed the reviewers concerns well in the revised version.

> -- Figure 5: E: it is unclear how many cells are there in fact. If points are overlaid, please arrange them in the way you use in Figure 4.

We would prefer to keep the 5E layout, consistent with the panels C and D, but added the numbers of cells to the legend.

> -- Figure 7: Consider different, more distinct colors, clarify legend.

We have re-coloured Figure 7 according to the Colour Universal Design scheme for 3 channel colours. We have also revised the legend.

[^1]: These authors contributed equally to this work.
